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CHAPTER I 
 
INTRODUCTION 
 
1. Study of pyrrolo[2,1-c] benzodiazepine natural products 
 
1.1 Overview of pyrrolo[2,1-c] benzodiazepine natural products 
Pyrrolo[2,1-c] benzodiazepine (PBD) natural products are produced by 
various actinomycetes and exhibit potent and broad-spectrum biological activities. 
Representative examples of PBDs are anthramycin, tomaymycin, sibiromycin, 
neothramycins and DC-81 which are structurally and biosynthetically related 
microbial natural products (figure 1-01).1-4 The biological activities of PBDs are 
due to their unique sequence-selective DNA-binding ability and consequently the 
inhibition of both DNA and RNA synthesis.5 Two other classes of natural products 
identified to be able to interact with DNA are: (1) berenil and netropsin which can 
form noncovalent bonds at AT rich region in the minor groove of DNA6, 7 and (2) 
daunomycin which can intercalate into base pairs of DNA using its aromatic ring.8   
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Figure 1-01. Representative examples of Pyrrolo[2,1-c] benzodiazepine. 
 
PBDs are structurally constituted by a tricyclic system with an aromatic A-
ring, a pyrrolidine C-ring and a common structural feature of a seven-membered 
B ring: pyrrolo(1,4)benzodiazepine nucleus. This pyrrolo(1,4)benzodiazepine 
nucleus possessing a N10-C11 imine-carbinolamine moiety is the key 
constitutional element for their biological activities because PBDs can bind with 
the minor groove of DNA by forming a covalent bond between their C11 position 
and exocyclic N2 amine of the guanine residue from double-stranded DNA (figure 
1-02).5, 9, 10 PBDs can lead to distortion of double-stranded structure by fitting into 
the minor groove of B-form DNA.11 In terms of the DNA sequence preference, 
footprinting experiments have demonstrated that the adducts of PBDs and 
double-stranded DNA span 3 base pairs with different sequence specificities, 
although these PBDs share similar mechanisms for the covalent bond formation 
and inhibition of DNA synthesis. The different sequence specificities of PBDs 
have the potential to play very important roles in their biological activities.  
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Figure 1-02. Proposed mechanism for the reaction of PBDs with DNA. 
 
Despite the structural similarities among PBDs, there are still dramatic 
differences in their structures which have been demonstrated to have great 
effects on their biological activities. The most commonly seen structural 
variations of PBDs are: (1) the substitution pattern on the left aromatic A-ring, (2) 
the length difference of the side chain at C-2 position on pyrrolidine C-ring and (3) 
the degree of unsaturation between C-2 and C-3 on pyrolidien C-ring (figure 1-
03).  
 
 
 
 
Figure 1-03. The structures of PBDs are mainly different in three parts. 
 
The common carbinolamine N10-C11 group is the key for PBDs potent 
activity and can be reversibly converted to two C-11 isomers with sibiromycin as 
an exception because a C1-C11-C11a-N10 conjugated imine is formed in the 
dehydration product of sibiromycin.3 This resulting imine structure from 
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sibiromycin is less susceptible to nucleophilic attack for adduct formation with 
DNA and makes sibiromycin less reactive. 
Anthramycin is the first example of PBDs and was isolated in 1963 from 
the fermentation broth of a thermophilic actinomycete Streptomyces refuineus var. 
thermotolerans found in a compost heap.12 Anthramycin was originally named 
"refuin" because it was believed to be a protein. Subsequently this biologically 
active compound was called "anthramycin" after the elucidation of its chemical 
structure because of the anthranilic acid derived A-ring of anthramycin. Total 
synthesis of anthramycin as well as X-ray crystallography have been performed 
to further confirm the structure and stereochemistry of anthramycin.13, 14  
Sibiromycin is the second example of PBDs and was produced by an 
actinomyces strain Streptosporangium sibiricum in Russia. Sibiromycin is the 
only PBD natural product that contains an amino sugar sibirosamine. The 
stereochemistry at C-11 position of sibiromycin has not been solved yet. Similar 
to anthramycin, sibiromycin exhibits both antitumor and antibacterial activities. 
Sibiromycin is very sensitive to acid and easily converts to an inactive product 
after an acid treatment.15 
Tomaymycin is another example of PBDs and was reported in 1972. 
Tomaymycin is produced by Streptomyces achromogenes var. tomaymyceticus 
isolated from a soil sample in Musashikoganei-city from Japan. The chemical 
structure of tomaymycin was confirmed by complete chemical synthesis.16  
Neothramycins were isolated from Streptomyces No. MC916-C4 and 
exhibit both antitumor and antibacterial activities. There are two stereoisomers of 
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neothramycin: neothramycin A and neothramycin B in equal amount from their 
producer. Neothramycin A and neothramycin B are different in the 
stereochemistry at C-3 position and interchangable in aqueous solution.17, 18  
DC-81 is a Pyrrolo[2,1-c] benzodiazepine natural product produced by 
Streptomyces roseiscleroticus with potent activity for the inhibition of nucleic acid 
biosynthesis. Recently there have been attempts made to design and synthesize 
DC-81 analogs, affording enhanced biological activities.19-21  
Other identified PBDs include RK1441A and RK144B from Streptomyces 
sp. RK1441.22 Both RK1441A and RK1441B show antibacterial activity, but only 
RK1441A exhibits antitumor activity.23 Chicamycin is another example isolated 
from Streptomyces sp. (J576-99) and can bind to double-stranded DNA more 
tightly than neothramycin. Chicamycin with an α hydroxyl group at C-2 position 
shows more potent biological activity than its synthesized isomer with a β 
hydroxyl group at the same position.24 Two other isolated anthramycin-like 
natural products are mazethramycin from Streptomyces thioluteus ME561-L425 
and porothramycin from Streptomyces albus.26 The simplest PBD identified so far 
probably is abbeymycin produced by an actinomycete AB-999F-52 isolated from 
a soil sample in Oregon, US. Abbeymycin exhibits no modification on the 
aromatic A-ring and no side chain at C-2 position of proline C-ring. Abbeymycin 
most likely exhibits weak antibacterial activity due to the above simple structural 
features(figure 1-04).27  
 
 
 
 
6 
 
 
 
 
 
 
 
 
Figure 1-04. Other examples of Pyrrolo[2,1-c] benzodiazepine (PBD) natural 
products. 
 
Anthramcin as well as other PBDs are usually isolated in the form of 
chemically stable C11-methyl ether PBDs if the isolation of PBDs is through 
recrystallization from hot methanol-water.28 Methyl ether derivatives of 
anthramycin and tomaymycin can be rapidly hydrolyzed to anhydromycin and 
yield corresponding PBDs with epimerization at C-11 position, whereas 
sibiromycin methyl ether can not be easily converted to sibiromycin from 
anhydrosibiromycin.15 The biological activities of PBDs methyl ether derivatives 
are basically equivalent to those of their parent PBDs.1, 29  
 
1.2 Biosynthetic study of benzodiazepine natural products 
Similarly structured elements among PBDs suggest that they might derive 
from similar building blocks through common biogenetic origins and biosynthetic 
pathways. Based on the results of feeding experiments, the biosynthesis of PBDs 
N
H
NHO
O
H3CO
H
N
H
NHO
O
H3CO
H
OH
H OCH3
RK-1441A
Streptomyces RK-1441
O
H OH
RK-1441B
Streptomyces RK-1441
N
H
NHO
O
H3CO
H
OCH3
OH
chicamycin A
Streptomyces sp. J576-99
N
H
N
OH
H3C
NH
O
O
OH
CH3
mazethramycin
Streptomyces thioluteus
N
H
N
OCH3
N
O
O
OH
H
CH3
CH3
porothramycin
Streptomyces albus
N
H
N
O
H
OH
OH
abbeymycin
actinomycete AB-999F-52
 
 
7 
requires the involvement of several amino acids and glucose. The anthranilate A-
rings of PBDs are derived from L-tryptophan through the kynurenine pathway and 
the pyrrolidine proline C-rings are derived from tyrosine through L-dopa 
intermediate and losing two aromatic carbons after the aromatic ring cleavage. 
Methionine is also required for the biosynthesis of some PBDs to provide extra 
methyl groups for the C-methylated aromatic A-ring and the unique C-1 unit in 
the side chain of pyrrolidine C-ring. The only amino sugar in sibiromycin is 
believed to be derived from D-glucose (figure 1-05).  
 
 
 
 
 
 
 
 
Figure 1-05. Building blocks of anthramycin, tomaymycin and sibiromycin. 
 
To date, the biosynthesis study of PBDs has been only focused on three 
representative examples, anthramycin, tomaymycin and sibiromycin, primarily 
based on the isotopic feeding studies. The aromatic A-ring of PBDs is derived 
from the amino acid tryptophan with different substitutions on it for each PBD30. 
As can also be inferred from the sequence information from the identified 
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anthramycin biosynthetic gene cluster in its producer S. refuineus, the left 
aromatic A-ring possibly comes from tryptophan via the kynurenine primary 
metabolic pathway and the substitutions may occur at the kynyrenine formation 
stage or as the last biosynthetic step right before the final formation of PBDs.30  
1.2.1 Biosynthetic study of anthranilate A-ring in PBDs 
Anthranilic acid is the basic precursor of anthranilate A-ring in all PBDs, 
but [COOH-14C] anthranilic acid could only be efficiently fed into tomaymycin 
rather than anthramycin or sibiromycin. Another possible substrate for the 
biosynthesis of the left anthranilate A-ring part, at least for anthramycin and 
sibiromycin, is 3-hydroxy-4-methylanthranilic acid. Interestingly, although 
anthramycin and sibiromycin share the same chemical structure for the aromatic 
A-ring subunit, anthramycin producer S. refuineus failed to take up either 
anthranilic acid or 3-hydroxy-4-methylanthranilic acid. Whereas sibiromycin 
producer Streptosporangium sibiricum could take up both compounds and only 
3-hydroxy-4-methyl-[2-14C]anthranilic acid could be incorporated into sibiromycin. 
Based on competition experiments among different possible substrates, 
kynurenine, 3-hydroxykynurenine,  3-hydroxy-4-methylkynurenine and 3-hydroxy-
4-methylanthranilic acid are possible intermediates for the biosynthesis of 
anthranilate A-ring in sibiromycin.30  Potential reasons for above observations are: 
(i) the anthranilate A-ring of tomaymycin is different from that of anthramycin and 
sibiromycin, so a sequentially different pathway is possibly required for the 
biosynthesis of the aromatic A-ring in tomaymycin, (ii) since sibiromycin shares 
the same anthranilate A-ring with anthramycin and can take up 3-hydroxy-4-
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methylanthranilic acid as an intermediate, 3-hydroxy-4-methylanthranilic acid is 
possibly an important intermediate for the biosynthesis of anthramycin but the 
membrane permeability of anthramycin producer S. refuineus for this 
intermediate may be a problem, (iii) another possibility is that anthramycin uses a 
complete different biosynthetic pathway for the anthranilate A-ring. If this is the 
case, then three different biosynthetic pathways for the anthranilate A-ring part 
may exist for above three PBDs natural products. 
On the anthranilate A-ring of sibiromycin, there is one additional hydroxyl 
group at C-7 position, which can also be found in other PBDs like tomaymycin 
and neothramycins. In the labeling experiments using DL-[5-3H] tryptophan as a 
precursor, 3H was detected in the C-6 position in the final chemical structure of 
sibiromycin probably because of the involvement of an NIH shift during the 
hydroxylation at C-7 position (figure 1-06).31  
 
 
 
 
 
 
 
Figure 1-06. An NIH shift is proposed to be involved in sibiromycin biosynthesis. 
 
In summary, the left aromatic A-ring is derived from tryptophan through the 
primary metabolic kynurenine pathway in which L-tryptophan is sequentially 
converted to N-formylkynurenine, L-kynurenine, 3-hydroxylkynurenine, 3-
hydroxy-anthranilic acid and possibly 3-hydroxy-4-methylanthranilic acid. The 
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questions that remain to be answered are: the sequence for the bioconversion 
from tryptophan to 3-hydroxy-4-methylanthranilic acid and especially at what 
stage the C-methyl group is introduced into PBDs (figure 1-07). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-07. Proposed biosynthetic pathway for 3-hydroxy-4-methylanthranilic 
acid. 
 
1.2.2 Biosynthetic study of dehydroproline in PBDs 
The most intriguing aspect related to the biosynthesis of PBDs is the 
biosynthetic pathway of their C-7 branch point compounds derived from L-
tyrosine. So far progresses in this area are primarily accomplished by Dr. 
Laurence H. Hurley lab and a series of feeding experiments using dual labeled 
(3H/14C) and 2H-labeled substrates had been employed to elucidate these partial 
biosynthetic pathways for the five-member rings and C2/C3 side chains in PBDs.  
For the formation of five-member rings in PBDs, L-tyrosine is first 
converted to intermediate L-dopa with subsequent cleavage of two carbon atoms 
in the aromatic ring of tyrosine. In terms of the cleavage of two carbon atoms, 
theoretically there are several possible routes for the conversion from L-tyrosine 
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to the five-member ring. But feeding experiments supported the route in which 
the π bond between C5 and C6 in tyrosine was broken prior to the formation of 
five-member rings and ruled out some other impossible biosynthetic pathways of 
the five-member rings in PBDs. Next the amine group attacks the C5 aldehyde to 
form a five-member ring from C2-C5, followed by the cleavage of another carbon 
atom at C7 position. After the formation of a C-7 compound, an extra C-1 unit will 
be transferred to the end of the C-2 side chain from L-methionine in the case of 
anthramycin and sibiromycin (figure 1-08).32  
 
 
 
 
 
 
 
 
 
 
Figure 1-08. Proposed biosynthetic pathways from L-tyrosine to dehydroproline 
in PBDs and lincomycin. 
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example of such C3-proline structure containing natural products after the 
isolation and characterization of lincomycin A from Streptomyces lincolnensis. 
Another unique structure about anthramycin is the existence of an amide 
carbonyl group which is believed to be derived from the S-methyl group of 
methionine, whereas both sibiromycin and lincomycin A contain a methyl group 
instead of an amide carbonyl group at the end of the C3-proline moiety. 
Tomamycin and lincomycin B contain a C2-proline side chain at the same C-2 
position of proline C-ring and this complete C2-proline moiety has been proven to 
be derived from L-tyrosine after the aromatic ring cleavage. Interestingly, only 
one form of PBD with either a C2 or a C3 proline moiety could be formed by its 
producer. But in the case of lincomycin, two forms of lincomycin with C2 or C3 
proline moiety have been detected from the fermentation broth of their common 
producing strain (figure 1-09).  
 
 
 
 
 
Figure 1-09. Two forms of lincomycin from Strptomyces lincolnensis. 
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anthramycin biosynthetic gene cluster was confirmed by gene disruption 
methods. In anthamycin biosynthetic gene cluster, an NRPS (nonribosomal 
peptide synthase) is involved in the biosynthesis of anthramycin and can 
assemble its two important intermediates: 3-hydroxy-4-methylanthranilic acid and 
dehydroproline acrylamide to yield anthramycin. Notably, anthramycin is probably 
released from the NRPS by a reductive mechanism because of the existence of 
an unusual reduction domain after the thioesterase domain (figure 1-10).  
 
 
 
 
 
Figure 1-10. Nonribosomal assembly of anthramycin in Streptomyces refuineus. 
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oxotomaymycin is due to a constitutive intracellular enzyme, rather than an 
intercellular enzyme, produced by tomaymycin producer S. achromogenes.33 
Very similar to anthramycin, tomaymycin also contains a N10-C11 carbinolamine 
functional group. So the unidentified tomaymycin biosynthetic gene cluster from 
S. achromogenes very possibly harbors an NRPS with a special reduction 
domain leading to the formation of carbinolamine in tomaymycin. If there is 
indeed a reduction domain in the NRPS for the biosynthesis of tomaymycin or at 
least a reduction reaction is required right before the final formation of 
tomaymycin, then why tomaymycin is further oxidized to oxotomaymycin is really 
very interesting. 
 
 
 
 
 
Figure 1-11. tomaymycin and oxotomaymycin from S. achromogenes. 
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the proline five-member ring as well as the incorporation of C2/C3 side chains.  
 
1.3 Biological activities of benzodiazepine natural products 
PBDs are very well known for their potent biological activities, especially 
antitumor and antibacterial activities, because of their ability to form covalent 
adducts with double-stranded DNA in an irreversible manner and inactivate DNA 
as a template for the biosynthesis of DNA and subsequently RNA in both 
eukaryotic and prokaryotic cells. But PBDs have been shown to have little effect 
on protein synthesis.9, 34 Because of their potent antitumor activity, some PBDs 
have been developed for drugs in the treatment of cancer and used clinically. 
However, these PBD natural products exhibit dose-limiting cardiotoxicity, which 
dramatically restricts their clinical applications and further development in drug 
discovery. But considering their unique mechanisms of action and lack of other 
toxicities, recently researchers have designed and synthesized diverse chemical 
analogs derived from PBDs to reduce their toxicity and increase their 
corresponding potency and activity.  
PBDs like anthramycin, sibiromycin and tomaymycin share very similar 
mechanisms for their biological activities and compete for the same guanine 
residue binding sites in double-stranded DNA. These natural products have been 
proven to be cable to forming highly specific and stable covalent bonds between 
C-11 position and N-2 position of guanine in double-stranded 
polydeoxynucleotides without dramatic distortion of the DNA helix. The PBDs-
DNA covalent adduct is believed to be formed after the nucleophilic attack from 
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the N2 amine group in double-stranded DNA towards N10-C11 imine 
intermediate via an SN1 mechanism. Other possible positions on DNA that could 
be modified by anthramycin are N-7, N-3 and C-8, but these possible 
modifications have been ruled out by assay experiments using labeled guanine.35 
The hydrogen bonding between C9 hydroxyl group and O2 of cytosine can also 
further stabilize the PBD-DNA adduct. PBDs don not cross-link DNA, so probably 
only one covalent bond is found in PBD-DNA adducts. Unlike other natural 
products, for example bleomycin which requires metal ions for its therapeutic 
effect36, PBDs do not require the presence of other cofactors for their potent 
biological activities.  
In terms of DNA binding properties, the order for the degree of DNA 
modification of natural-occurring PBDs is sibiromycin > anthramycin > 
tomaymycin > DC-81 > neothramycin.37, 38 Despite their small molecular weights, 
PBDs exhibit great sequence specificity and prefer covalent binding with DNA 
sequences flanked by purines rather than pyrimidines with 5'PuGPu as the most 
preferred binding sequence and 5'PyGPy the least preferred sequence for 
PBDs.39 The rate for the formation of adducts between PBDs and DNA is 
relatively slower than that of other DNA binding compounds which can interact 
with DNA within a few seconds, for example it takes 1 hour for the reaction 
between anthramycin and DNA to complete in vitro.37 
1.3.1 Biological activity of anthramycin 
Anthramycin is the most extensively studied PBD natural product in the 
aspect of both biosynthesis and biological activity. Anthramycin is detected from 
 
 
17 
the fermentation broth of S. refuineus via cup-plate assay method using Sarcina 
lutea and Bacillus sp. TA as test strains. During the course of anthramycin 
extraction, anthramycin could be converted into either anthramycin methyl ether 
after crystallization from boiling methanol-water or anhydroanthramycin after 
crystallization from boiling acetone. Interconversion between anthramycin methyl 
ether and anhydroanthramycin could also be observed. There is no dramatic 
difference between the biological activities of anthramycin and anthramycin 
methyl ether.  When anthramycin methyl ether was dissolved in water, three 
forms of anthramycin could be detected: anthramycin, C11-epi-anthramycin and 
anhydroanthramycin.1  
Anthramycin can inhibit the synthesis of doubled-stranded DNA by forming 
covalent bond with the 2-amino group of guanine and remains hidden in the 
minor groove of DNA, but will not react with poly(dI)poly(dC) because they lack a 
N2 amine group. Based on the X-ray crystal structure analysis of a covalent 
anthramycin-DNA adduct, anthramycin can lead to a low twist of double-stranded 
DNA after its binding with DNA, but hydrogen bonds between C9 hydroxyl group 
and N10 as well as the acylamide bond tail and base pairs in the minor groove 
can also contribute to the stabilization of anthramycin-DNA adduct.40 Anthramycin 
binding sites have been well studied and it has been shown that the bonding 
formation of anthramycin-DNA adducts is strongly influenced by the neighboring 
bases of guanine and exhibits dramatic specificity and selectivity. However, for 
anthramycin, the preferred sequence of triplets is AGA, AGG > GGA > GGG.41 
But base sequence rather than the overall base composition of DNA is believed 
 
 
18 
to be the determinant for the reaction rate between anthramycin and DNA. For 
example Cl. perfrignens DNA with 37% GC and more fast-reacting sites reacts 
faster with anthramycin than M. lysodeikticus with 72% GC and less fast-reacting 
sites.  In addition, the binding of anthramycin to double-stranded DNA is very 
sensitive to the formation of DNA.10 
Actually anthramycin alone can not lead to single or double strand DNA 
breakage, but anthramycin possesses the ability to cause in vivo excision-
dependent single and double strand breaks in DNA. One explanation for this 
might be that the cleavage of DNA by anthramycin is caused by the self-repair 
system which is cable of recognizing anthramycin-DNA adducts. The cleavage of 
DNA caused from anthramycin are dose-dependent and can occur at a very low 
concentration of anthramycin.42 The mechanism of anthramycin-caused DNA 
cleavage is very unique and dramatically different from that of other DNA-binding 
natural products like bleomycin and daunomycin.43, 44 Another possible source of 
the biological activity of anthramycin is via the inhibition of the interaction 
between DNA and its transcription factor Sp1 and further inhibition of RNA 
biosynthesis.45  
Anthramycin has a broad spectrum activity in vitro against a wide variety 
of tumor cell lines such as monkey kidney, rabbit kidney cells, HeLa cells, 
Sarcoma 180, Walker 256 carcinosarcoma, human epithelioma No.3, leukemias 
P388, and human adenoma, etc. Other pharmacological results showed  that 
anthramycin was able to cause nuclear segregation in Kupffer cells, endocrine 
and exocrine pancreatic cells, proximal tubular cells of the kidney and in the 
 
 
19 
reticuloendothelial cells from spleen in rats.46 Anthramycin has also been 
demonstrated to be able to inhibit gastrointestinal, breast neoplasms, lymphoma 
and sarcomas in its evaluation in humans.47 But anthramycin did not show 
biological activity against leukemia L1210 and plasma cell tumor YPC-1.29 As to 
its antimicrobial activity, anthramycin is in vitro most active against gram-positive 
bacteria, streptomycetes, mycobacteria, Escherichia coli B and weakly active 
against fungi and yeasts. But anthramycin has been found to be inactive for its 
antimicrobial activity in vivo.29, 48 Anthramycn also exhibits some other biological 
activities, for example amebicidal and chemosterilant activities.   
Anthramycin is a potent antitumor natural product, which can inhibit the 
synthesis of DNA but can not affect the functions of the DNA of its producer S. 
refuineus. Anthramycin producer S. refuineus has been proven to be able to take 
in tomamycin and sibiromycin and is sensitive to them because they can inhibit 
the DNA synthesis of S. refuineus. As mentioned above, anthramycin, tomamycin 
and sibiromycin share similar biological mechanisms to inhibit DNA synthesis and 
can competitively bind to the same sites on double-stranded DNA. Besides, it 
has also been shown that intact cells are necessary for the total biosynthesis of 
anthramycin from S. refuineus. Based upon above experiments, anthramycin is 
very possibly biosynthesized in the cell wall and periplasmic space and can not 
have contact with functional double-stranded DNA in S. refuineus.49  
1.3.2 Biological activity of sibiromycin 
Sibiromycin stands out as the only example in PBDs that contains an 
amino sugar (sibirosaminide) at C-7 position of aromatic A-ring and is the most 
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potent natural product of the PBDs.50 The binding ability between sibiromycin and 
double-stranded DNA is reinforced by the electrostatic forces from this extra 
sugar and the phosphate groups of the backbone of DNA.51  
Under mild acidic conditions it has been proven that sibiromycin is 
unstable and can easily turn into anhydrosibiromycin by losing a molecule of 
water. But under acidic conditions, sibiromycin tends to lose its aminosugar 
moiety to yield anhydrosibiromycinone. Both anhydrosibiromycin and 
anhydrosibiromycinone are very stable compounds but unfortunately biologically 
inactive.3, 15  
Sibiromycin can inhibit the growth of some bacteria like Bacillus mycoides, 
Bacillus subtilis, Staphylococcus aureus and Escherichia coli. Sibiromycin is very 
well known for its activity in the treatment of cancer cells such as praegastric 
cells and lymphosarcoma cells.15  
1.3.3 Biological activity of tomaymyicn 
Tomaymycin is able to bind with the exocyclic 2-amino group of guanine in 
DNA. The neighboring bases also influence the covalent bonding between 
tomaymycin and double-stranded DNA. The preferred order sequence of triplets 
for tomaymycin is AGA > GGC, TGC > AGC with AGA being the most preferred 
triplet sequence for both anthramycin and tomaymycin. But there are still 
dramatic differences as to DNA triplet preference for tomaymycin and 
anthramycin, so DNA saturated with tomaymycin can still react with 
anthramycin.41 Tomaymycin can lead to greater conformation changes of double-
stranded DNA than anthramycin and the DNA binding sequence specificity has 
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great effect on the degree of bending and the reaction rate between PBDs and 
DNA.52  
Based on the Corey-Pauling-Koltun (CPK) model building studies, the 
stereochemistry of the covalent bonding site between DNA and PBDs including 
anthramycin, tomaymycin, sibiromycin and neothramycins had been assigned as 
S. However, a later report derived from a recombination of fluorescence, high-
field NMR and molecular modeling methods demonstrated that tomaymycin 
could yield 11S, 11aS and 11R, 11aS diastereomeric adducts with opposite 
orientations in the minor groove of double-stranded DNA because of the 
epimerization of tomaymycin at the C-11 position via 10,11-
anhydrotomaymycin(figure 1-12).11 Using similar approaches, it has been 
proposed that DNA and anthramycin with a similar N10-C11 imine structure can 
form covalent adduct with an 11S stereochemistry.53, 54 But further 
characterization studies of tomaymycin-DNA adduct using proton NMR showed 
that tomaymycin bound to 5’-CGA with an S stereochemistry at C-11 position and 
the orientation of PBDs connected with double-stranded DNA as well as the 
stereochemistry at C-11 position were largely due to the DNA binding sequence 
and the chemical structure of PBDs.55  
 
 
 
Figure 1-12. Proposed mechanism for epimerization of C-11 of tomaymycin. 
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There is an unsaturated double bond at C-2 position of tomaymycin. NMR 
spectra data as well as X-ray crystallography studies confirmed the configuration 
of C-2 side chain to be E-tomaymycin instead of Z-tomaymycin.51, 56 Later, total 
synthesis of Z-tomaymycin has also been reported, showing similar biological 
activity to the naturally occurring E-tomaymycin (figure 1-13)57.  
 
 
 
 
 
 
 
Figure 1-13. E-tomaymycin from S. achromogenes and its synthesized isomer Z-
tomaymycin. 
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of the absence of a hydroxyl group at C-9 position in neothramycin.58 
Neothramycin has been shown to inhibit the growth of bacteria such as E. coli 
and exhibit activity against mouse lymphoblastoma L5178Y and HeLa cell lines.17  
1.3.5 Biological activity of tomaymycin and DC-81 
The chemical structures of tomaymycin and DC-81 are very similar. The 
major structural difference between them is the existence of one addition exo 
unsaturated group at C2 position in tomaymycin, which is probably the reason 
why tomaymycin is more potent than DC-81. Some tomaymycin analogues with 
similar C2 unsaturated structures have been successfully synthesized and the 
pharmacological experiments have proven the importance of C2-unsaturation, 
which can enhance both DNA-binding ability as well as cytotoxicity.  
1.3.6 Relationship between the chemical structures and biological activity of 
PBDs 
A series of PBD analogues have been synthesized to study the 
relationship between PBDs structure and their biological activity. Modifications on 
pyrrolidine C-ring and the substitutions of aromatic A-ring have been achieved 
based on antitumor agent DC-81. Toxicity studies showed that functional group 
substitutions in the pyrrolidine C-ring, particularly the C2-C3 unsaturation or C2 
side chain was very important for the binding affinity and cytotoxicity.59 The 
presence of either C2-C3 endo unsaturation in the pyrrolidine C-ring or C2 exo 
unsaturaturation can enhance the DNA binding ability and activity of PBDs in 
vitro.60, 61 Neither anthranilic acid nor 3-hydroxyanthranilic acid (figure 1-14) can 
form adducts with double-stranded DNA and inhibit the biosynthesis of DNA and 
RNA. These two structural building blocks of PBDs have no biological activities 
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toward cell lines as their parent PBDs do and the changes of the substitutions on 
the aromatic A-ring did not dramatically improved the corresponding biologically 
activities of PBDs. This illustrates that the anthranilic acid A-ring moiety in PBDs 
is not solely responsible, or at least not enough, for the overall biological 
activities of PBDs.  
 
 
 
 
Figure 1-14. anthranilic acid and 3-hydroxyanthranilic acid. 
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cardiotoxicity. Many studies supported the conclusion that PBDs and DNA were 
connected by a covalent bond and further stabilized by hydrogen bonding 
interaction between them. Recently a structurally similar synthetic compound with 
a 2-naphthyl group at C-2 position of tomaymycin shows high binding affinity with 
double-stranded DNA and has been demonstrated to be able to stabilize the 
corresponding adduct predominantly by hydrophobic (van der Waals) interactions 
because of the planar hydrophobic groups at C-2 position.62  
 
2. Biosynthesis of nitro sugar and arylnitro group in natural products 
 
2.1 Biosynthesis of nitro sugar containing natural products 
2.1.1    Biosynthesis of deoxyaminosugars  
In the past twenty years, secondary metabolites from bacteria, especially 
a wide variety of sugar containing natural products, have been extensively 
studied. Glycosylated natural products exhibit potent biological activities and it 
has been demonstrated that decorating sugars play very important roles in the 
activities of their parent compounds.63-65 For bacteria and other microorganisms, 
secondary metabolites are of great ecological importance and generally used as 
defenses against predators, parasites and for interspecies competition. 
Secondary metabolites produced by microorganisms can be used in drug 
discovery and other biotechnology fields.66  
Deoxyaminosugars are deoxysugars containing amino groups or amino-
derived groups and are biosynthesized by a variety of organisms, including 
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fungal, bacterial and botanical sources. Deoxyaminosugars play significant roles 
in the structures of lipopolysaccharides (LPS)67, 68 and extracellular 
polysaccharides (EPS)69 as well as the biological functions of natural products70 
from their producers. Of the above functions, we are mostly interested in the 
biosynthesis and functional studies of highly modified deoxyaminosugars 
produced by microorganisms, specifically bacteria.  
Deoxyaminosugars are generally derived from precursors such as glucose 
6-phosphate or fructose 6-phosphate through both primary metabolic pathways 
and secondary metabolic pathways. Genes for the biosynthesis of 
deoxyaminosugars can generally be identified in the complete gene clusters for 
the biosynthesis of their corresponding deoxyaminosugars containing natural 
products but are not always clustered together. The genes for the biosynthesis of 
deoxyaminosugars are relatively conserved and generally code for dehydratases, 
ketoreductases, isomerases, methyltransferases and aminotransferases etc. 
After a series of enzymatic transformations on their common precursors, the 
modified deoxysugars are attached to the final natural products by 
glycosyltransferases. Amino groups generally occur at the C2, C3, C4 and C6 
positions on the deoxyaminosugars. C3 and C4 amino sugars containing 
deoxyaminosugars are mostly identified on aromatic and macrolide polyketides, 
nonribosomal peptides and oligosaccharides.71, 72 C2 and C6 amino sugars are 
generally found in aminoglycosides.73  
The most common precursor for the biosynthesis of deoxyaminosugars as 
well as other deoxysugars is glucose 6-phosphate which is derived from D-
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glucose by an anomeric hexose kinase. Glucose 6-phosphate can be 
subsequently converted to NDP-α-D-glucose and then a key intermediate in 
deoxysugar biosynthesis, NDP-4-keto-6-deoxy-α-D-glucose, from which many 
diversely modified deoxysugars including deoxyaminosugars are derived. 
Deoxyaminosugars originated from NDP-4-keto-6-deoxy-α-D-glucose include 
TDP-D-desosamine, TDP-D-forosamine, TDP-D-vancosamine, TDP-L-
daunosamine and TDP-D-mycaminose. Another common precursor for the 
biosynthesis of deoxyaminosugars is fructose 6-phosphate. Fructose 6-
phosphate is converted to GDP-D-mannose which can be further modified to 
produce different NDP sugars (figure 1-15).74  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-15. Two common precursors for deoxyaminosgurs: NDP-4-keto-6-
deoxy-α-D-glucose (a) and fructose 6-phosphate (b). 
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interaction between the 14-membered ring macrolides and the ribosome target.75-
78 Besides, the amino group is also involved in the signal interaction among 
natural products or their producers.79  
2.1.2 Examples of aminosugars from natural products 
In the past several decades, a large number of amino sugars from natural 
products that contain diverse substitutions and structures have been reported. 
They are derived from the two common precursors: glucose 6-phosphate and 
fructose 6-phosphate. The biosynthetic pathways for some of the intriguing 
amino sugars from microbial natural products have been extensively investigated 
(figure 1-16).  
 
 
 
 
 
 
 
 
 
Figure 1-16. Examples of NDP-deoxyaminosugars from natural products. 
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by different species. One of the most well known natural product is erythromycin 
from Saccharopolyspora erythraea.80 Erythromycin possesses two sugars, D-
desosamine and L-cladinose, which are attached to a 14-membered ring 
biosynthesized by polyketide synthase (PKS). The erythromycin biosynthetic 
gene cluster has been reported81 and the biosynthesis of D-desosamine requires 
the involvement of five genes coding for isomerase, aminotransferase, 
dehydratase and 3,4-reductase and methyltransferase (figure 1-17). Other D-
desosamine containing natural products include oleandomycin from 
Streptomyces antibioticus82 and methymycin/pikromycin from Strptomyces 
venezuelae.83  
 
 
 
 
 
Figure 1-17. Biosynthetic pathways of NDP-D-desosamine and NDP-D-
mycaminose. 
 
2.1.2.2 D-Mycaminose 
Tylosin, isolated from Strptomyces fradiae T59235, contains a 16-
membered ring macrodide decorated with three dexosugars, one of which is 
mycaminose.84 Notably, two genes for the biosynthesis of the general deoxy 
sugar precursor NDP-4-keto-6-deoxy-α-D-glucose, tylAI and tylAII, exist in the 
tylosin biosynthetic gene cluster. Subsequently, the biosynthesis of D-
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mycaminose from NDP-4-keto-6-deoxy-α-D-glucose requires three tailoring 
enzymes: isomerase, aminotransferase and methyltransferase (figure 1-17).85  
2.1.2.3 Amino sugars in vancomycin family natural products 
Vancomycin is produced by Streptomyces orientalis and contains 
vancosamine, 3-amino-2,3,6-trideoxy-3-C-methyl-L-arabino-hexose. 
Chloroeremomycin with two epivancosamines, the 4-epi isomer of vancosamine, 
is another representative natural product in vancomycin family. Bahlimycin is 
structurally similar to vancomycin but possesses the 4-oxo form of 3-methyl-3-
amino trideoxyhexose (figure 1-18). The biosynthetic gene clusters for both 
chloroeremomycin and bahlimycin have been identified and the biosynthetic 
pathway for epivancosamine has been well studied in vitro. The vancomycin 
biosynthetic gene cluster has not been reported to date and the exact 
biosynthetic pathway for vancosamine has not been studied in vitro. Since the 
only difference between vancosamine and epivancosamine is the 
stereochemistry of 4-OH group, stereoisomers vancosamine and 
epivancosamine potentially share a similar biosynthetic pathway in which the 4-
keto group can be reduced to a hydroxyl group with either axial or equatorial 
stereochemistry by ketoreductase.74  
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Figure 1-18. Biosynthetic pathways for NDP-L-vancosamine and NDP-L- 
epivancosamine. 
 
2.1.2.4 Forosamine from Spinosyn 
Spinosyns are produced by Saccharopolyspora spinosa and consist of 
more than 25 derivatives with minor structural differences from the culture of the 
same strain.86, 87 Spinosyns contain two dexosugars, an amino sugar forosamine 
and tri-O-methylrhammnose, which are attached to a tetracyclic macrolide core 
biosynthesized by a polyketide synthase (PKS). Spinosyns show dramatic 
mosquito larvicidal and insecticidal activities probably by binding with the nervous 
system receptors and damaging the insect nervous system.88 The biosynthetic 
gene cluster for spinosyns has been identified and feeding experiments have 
been utilized to elucidate the biosynthetic pathway for spinosyns.89 In the 
biosynthetic gene cluster of spinosyns, five genes, spnONQRS, are proposed to 
be involved in the biosynthesis of forosamine and have been proven in vitro to 
encode 2,3-dehydratase, 3-ketoredutase, 3-dehydratase, aminotransferase and 
4-dimethyltransferase respectively (figure 1-19).89-94 Several other natural 
products including spiramycin, forosaminylgriseucin A and dunaimycin also 
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contain forosamine.95, 96  
 
 
 
 
 
Figure 1-19. Biosynthetic pathways for NDP-D-forosamine. 
 
2.1.2.5 Daunosamine from daunorubicin 
Daunorubicin is a representative example of the anthracycline natural 
products with a four fused-ring aromatic system biosynthesized by PKS.97 
Daunorubicin exhibits dramatic biological activity, in particular antitumor activity, 
and has been used clinically.98 Daunorubicin contains an amino sugar 
daunosamine which is of great importance for its biological activity.99 At least four 
genes are proposed to be responsible for the formation of daunosamine from the 
identified daunorubicin biosynthetic gene cluster and code for dehydratase, 
epimerase, aminotransferase and ketoreductase respectively (figure 1-20). But 
after the identification of the daunorubicin biosynthetic gene cluster, the detailed 
functions of some of the genes and the exact biosynthetic pathway for 
daunosamine have not been well elucidated.99, 100  
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Figure 1-20. Biosynthetic pathways for NDP-L-daunosamine. 
 
2.1.2.6 D-Mycosamine 
Nystatin is a natural product produced by Streptomyces noursei and 
contains a 38-membered macrolactone ring with a deoxyaminosugar, D-
mycosamine, attached at C-19 position. Other D-mycosamine containing natural 
products include amphotericin, candicidin, pimaricin and rimocidin.101-105 All the 
above natural products exhibit antifungal activity and their biological activity 
stems from their ability to promote leakage of the ion channel on the membrane 
by binding with the sterol targets of fungal cell membranes.106 The biosynthetic 
gene cluster for nystatin has been identified and three genes are proposed to be 
involved in the biosynthesis of D-mycosamine derived from GDP-D-mannose and 
fructose-6-phosphate(figure 1-21).107  
 
 
 
 
 
Figure 1-21. Biosynthetic pathways for NDP-D-mycosamine. 
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2.1.2.7 D-Perosamine 
Lipopolysaccharide (LPS) is a very important component for the 
membrane of some gram-negative bacteria like E. coli O157:H7.108 LPS plays a 
key role for virus infection by protecting the pathogen from the defense system of 
the host. LPS is composed of O-antigen, core oligosaccharide and lipidA.109-111 
O-antigen consists of four repeating units: N-acetyl-D-erosamine, L-fucose, D-
glucose and N-acetyl-D-galactose.112-114 N-acetyl-D-erosamine is another 
representative example of amino sugars derived from fructose-6-phosphate 
through the GDP-D-mannose intermediate. GDP-D-mannose is first oxidized by a 
dehydratase to GDP4-keto-D-mannose, which is subsequently converted to 
GDP-D-perosamine by an aminotransferase (figure 1-22).115  
 
 
 
 
Figure 1-22. Biosynthetic pathway for GDP-D-perosamine. 
 
2.1.2.8 Other amino sugars from natural products 
Besides the amino sugars mentioned above, there are still other amino 
sugars that exist in identified natural products. Biosynthetic pathways for these 
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O
OH
HO
HO
HO
ONDP
O
H3C
HO
HO
ONDP
ONDP-mannose
dehydratase
NDP-D-mannose
O
H3C
HO
HO
ONDP
H2Naminotransferase
GDP-D-perosamine
 
 
35 
streptomycin produced by Streptomyces griseus and Streptomyces 
glaucescens116, ristosamine in ristomycin produced by Proactinomyces fructiferi 
var. ristomycin117, ossamine in ossamycin produced by Streptomyces 
hygroscopicus var. assamyceticus118, 119, rhodosamine in megalomicin A 
produced by Micromonospora megalomicea120-123, and vincenisamine in 
vicenistation produced by Strptomyces sp. HC-34 (figure 1-16)124.  
 
2.1.3 Biosynthesis of nitro sugars from natural products 
Only a small portion of amino sugars as mentioned above can be oxidized 
to the corresponding nitro sugars which have been proven to be very important 
for the potent biological activities of their mother compounds. The biosynthetic 
pathways of nitro sugar and the mechanism for the formation of the nitro group 
remained uninvestigated for a long time, after the identification and 
characterization of some nitro sugar containing natural products. 
In the known nitro sugar containing natural products, deoxysugars share 
the same carbon skeleton, but stereochemistries of attached nitro groups may 
vary. Nitro sugar containing natural products are represented by everninomycin 
produced by Micromonospora carbonacea var. africana ATCC39149125, 
rubradirin produced by Streptomyces achromogenes var. rubradiris126 and 
kijanimicin produced by Actinomadura kijaniata127 as shown in Figure 1-23. The 
biosynthetic gene clusters for the above three natural products have been 
reported.128-130 These identified nitro sugar containing natural product 
biosynthetic gene clusters from their producers have provided a basis for us to 
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elucidate the biosynthetic pathways for the formation of their unique nitro sugars 
and characterize the functions of enzymes involved in the biosynthesis of nitro 
sugars.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-23. Structures of everninomycin, rubradirin and kijanimicin. 
 
2.1.3.1 Everninomycin 
Everninomycin belongs to the orthosomycin class of antibiotics and 
contains a nitro sugar and seven deoxysugar residues attached to modified 
orsellinic acid with amazing thirty-five asymmetric centers.128 Some other natural 
products belonging to the orthosomyicn family of antibiotic include curamycin, 
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olivamycin and avilamycin. Everninomycin antibiotics exhibit broad-spectrum 
biological activity against both Gram-positive and Gram-negative bacteria, 
notably some multidrug-resistant bacteria including penicillin-resistant 
streptococci, methicillin-resistant staphylococci and glycopeptide-resistant 
enterococci as well as bacteria resistant to vancomycin, which has been known 
as the “antibiotic of last resort”.131, 132 The fact is that so far there are not many 
alternative antibiotics to conquer infectious diseases, so the occurrence of 
everninomycins may provide another option to combat infectious diseases 
caused by the above multidrug resistance bacteria which have been very 
common in clinical settings. 
Like chloramphenicol, which is an important member of vancomycin family, 
everninomycin is effective against bacteria by the inhibition of protein synthesis, 
especially by binding to ribosomal protein L16 and subsequently affecting the 
functions of 50S ribosomal subunit.133-135 Everninomycin producer 
Micromonospora carbonacea var. africana can produce several other structurally 
related secondary metabolites differing in possession of an amine, 
hydroxylamine, nitroso or a novel alkoxyl group in the place of nitro group in 
everninomycin (figure 1-24). However, these structurally similar natural products 
from the same producer strain M. africana exhibit significantly different biological 
activities. For example, everninomycin with a nitro group at C65 is active again 
gram-positive bacteria with a mean Minimum Inhibitory Concentration (MIC) of 
0.03 mcg/mL for all the 22 tested Staphylococci strains, whereas the 
everninomycin derivative with an amino sugar at C65 is active again gram-
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positive bacteria with a mean MIC 2.2 mcg/mL for all the 11 tested Staphylococci 
strains and gram-negative bacteria with a mean MIC of 100.4 mcg/mL for all the 
57 tested strains. The range of activities in the everninomycin natural products 
indicates that the nitro group is critical for the biological activity of nitro group 
containing natural products.  
 
 
 
 
 
 
 
 
 
 
Figure 1-24. Everninomycin derivatives from Micromonospora africana. 
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everninomycin because the hydrolysis of orthoester linkages will inactive 
everninomycin. The phenolic hydroxyl at C1 is also imperative, because 
everninomycin derivatives with a methyl or allyl ether at C1 position do not exhibit 
activity. Interestingly, although the nitro group at C65 has been proven to have 
effect on everninomycin activity, the complete loss of the nitro sugar does not 
dramatically change biological activity of the corresponding new natural product. 
One everninomycin derivative with chemically modified acetamide structure at 
the original C65 nitro group position exhibits the highest biological activity.136  
Previously, only everninomycin derivatives with the amino sugar, 
hydroxylamino sugar, nitroso sugar or nitro sugar have been isolated from the 
broth of everninomycin producer M. africana. In recent years, some other 
oligosaccharide secondary metabolites with structural differences at other 
positions have also been reported. They are Sch 49088, Sch 58769, Sch 58773, 
Sch58775 and Sch 58777 (figure 1-24), the structures of which have been 
confirmed by NMR.137, 138 These novel oligosaccharide natural products are 
different from everninomycin mainly in the substitutions on the PKS derived 
aromatic ring, C-66 position on the nitro sugar group as well as the side chain on 
the H deoxysugar. Of note, natural product Sch 58773 contains a hydroxyl group 
instead of the everninomycin-harboring –OCH3 group at C-66 position on nitro 
sugar, meaning that the substitution on C66 position, at least changing from –
OCH3 to –OH, does not affect the N-oxidation of the amino sugar precursor to the 
nitro sugar.  
The biosynthetic gene cluster for everninomycins was reported in 2002.  
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The identification of everninomycins biosynthetic gene cluster greatly facilitates 
the elucidation of the everninomycin biosynthetic pathway, especially the 
formation of novel nitro sugar. In the everninomycin gene cluster that harbors 
more than 40 biosynthetic genes, seven genes are proposed to be involved in 
the biosynthesis of L-evernitrose from the common sugar precursor NDP-4-keto-
6-deoxy-a-D-glucose. These seven genes function in the sequential 2,3-
dehydration, amino transformation, C-methylation, epimerization, C-4 keto 
reduction, O-methylation and N-oxidation steps followed by the transformation of 
the mature deoxysugars onto everninomycin by a glycosyltransferase (figure 1-
25).  
 
 
 
 
 
 
 
Figure 1-25. Proposed biosynthetic pathway of TDP-L-evernitrose for 
everninomycin. 
 
2.1.3.2 Rubradirin 
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rubranitrose and is active against a variety of Gram-positive bacteria both in vitro 
and in vivo.126 Its antibacterial activity is due to its impairment of protein synthesis 
by selective inhibition of ribosomal functions.139-142 To date, the stereochemical 
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based on the biosynthetic pathway (figure 1-26) of rubranitrose in which there is 
no epimerase and the chemical synthesis of enantiomers of rubranitrose, 
rubranitrose should be assigned as D configuration and share similar 
biosynthetic pathway with D-kijanose in kijanimicin. Another intriguing result is the 
isolation of protorubradirin which is structurally different from rubradirin only in the 
nitroso group at the original nitro group. When the isolation of rubradirin was 
conducted in complete darkness, protorubradirin could be isolated from the broth 
of rubradirin producer S. rubradiris and then oxidized to rubradirin after its 
exposure to light. So it has been proposed that protorubradirin with a nitroso 
sugar is the true product produced by S. rubradiris and rubradirin is the oxidative 
product of protorubradirin.143  
 
 
 
 
 
 
Figure 1-26. Proposed biosynthetic pathway of NDP-D-rubranitrose in rubradirin. 
 
2.1.3.3 Kijanimicin 
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possesses significant antitumor activity.144 Sequence analysis of the identified 
107.6 kb kijanimicin biosynthetic gene cluster indicates that six genes are 
proposed to be involved in the biosynthesis of the nitro sugar (figure 1-27), D-
kijanose. One flavin dependent oxidase KijD3 shows high similarity with ORF36 
in the everninomycin gene cluster as well as RubN8 in the rubradirin gene cluster 
and is predicted to mediate the oxidation from an amino sugar intermediate to the 
final nitro sugar.130 
 
 
 
 
 
 
Figure 1-27. Proposed biosynthetic pathway for D-kijanose in kijanimicin. 
 
2.2 Biosynthesis of aryl nitro group containing natural products 
Nitro groups can also be found to be connected with aromatic groups in a 
large number of natural products. These aryl nitro natural products, mostly 
produced by bacteria and fungi, possess potent biological activities and have 
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microbial aryl nitro compounds with dramatic biological activities. 
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isolated from Streptomyces venezuelae. Chloramphenicol has been used 
clinically for the treatment of a great variety of infectious diseases. Other 
representative examples of the aryl nitro natural products include 
dioxapyrrolomycin produced by Streptomyces fumamus, 1-nitroaknadinine 
produced by plant Menispermaceae, thaxtomin produced by Stretomyces, 
pyrrolnitrin produced by Pseudomonas fluorescens and aureothin produce by 
Streptomyces thioluteus (figure 1-28). 
 
 
 
 
 
 
 
 
 
 
Figure 1-28. Representative examples of aryl nitro containing natural products. 
 
Aryl nitro functional groups are different from nitro sugars not only in their 
chemical structures. More importantly, they possess dramatic diverse 
mechanisms and biosynthetic pathways compared to that of nitro sugars that 
have been proven to be oxidized from amino sugars by N-oxidases. To date, 
there are mainly two mechanisms for the formation of arylnitro groups: direct 
nitration and enzymatic N-oxygenation.  
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2.2.1 Direct nitration mechanism for the biosynthesis of aryl nitro natural product 
The first class of mechanism for the biosynthesis of aryl nitro functionality 
is direct elctrophilic nitration of aromatic groups by NO2+ through which the nitro 
groups are introduced into the aromatic rings of natural products. This kind of 
nitration mechanism is dramatically different from the mechanism for the 
biosynthesis of nitro sugars in which an amino sugar is oxidized to a nitro sugar 
enzymatically. The first example of direct nitration was reported in 1989, with a 
biosynthetic investigation of the nitro group in dioxapyrrolomycin.145 
Dioxapyrrolomycin as well as its proposed precursor pyrrolomycin C missing the 
corresponding -NO2 at C4 can both be found from the culture of Streptomyces 
fumanus. Feeding studies have shown that the benzenoid ring is derived from 
three acetate units and the pyrrole ring is derived from L-proline.146, 147 Originally, 
the formation of nitro group on the pyrrole was proposed to be due to the 
oxidation of an amino group because a secondary metabolite 3-amino-L-proline 
was identified. Later incorporation experiments demonstrated that the 
introduction of C4 nitro group was dependent on the components in the medium. 
If 15N18O3- was used as the sole source of nitrogen in the medium for S. fumanus, 
all nitrogen and oxygen atoms in C4 nitro group on the pyrrole ring would come 
from 15N18O3-.148 This direct nitration step for the biosynthesis of 
dioxapyrrolomycin was also confirmed by in vitro treatment with HNO3 (figure 1-
29).149  
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Figure 1-29. Direct nitration mechanism for the biosynthesis of 
dioxapyrrolomycin. 
 
Another prominent example of direct nitration is related to thaxtomin which 
is a nitro-containing produced by plant pathogen Streptomyces turgidiscabies.150 
In the genome of Streptomyces turgidiscabies one nos gene exists upstream of 
thaxtomin biosynthetic gene cluster and shows high similarity with the nos genes 
in mammals.151 Nitric oxide (NO) produced by nitric oxide synthases (NOSs) 
identified in mammals have been recognized as a potent signal molecular and 
plays important roles in many body responses in mammals.152, 153 Gene 
disruption and complementation experiments have already shown the necessity 
of nos gene for the biosynthesis of thaxtomin.154 Further biochemical studies also 
proved that NOS could mediate the nitration reaction to produce L-4-
nitrotryptophan from the oxidation of NO during the biosynthesis of thaxtomin 
(figure 1-30).155, 156  
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Figure 1-30. Direct nitration involved in the biosynthesis of thaxtomin. 
 
2.2.2 Enzymatic oxidation in the biosynthesis of aryl nitro natural products 
The nitro groups from some other identified aryl nitro containing natural 
products are oxidized from amino groups by N-oxidase in their biosynthetic gene 
clusters. Although the oxidation reaction for the biosynthesis of aryl nitro 
structures seems similar to that for nitro sugars at first sight, the truth is that the 
formations of aryl nitro groups are mediated by N-oxidases with dramatic different 
oxidation mechanisms.  
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introduce the second chlorine onto the aromatic ring. PrnD is the last biosynthetic 
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enzyme responsible for the oxidation of an amino group to a nitro group. Further 
biochemical experiments in vitro proved the function of PrnD in the formation of 
arylnitro group. PrnD is a novel Rieske iron-sulfur cluster N-oxidase which is able 
to catalyze the arylamine oxidation reaction from aminopyrrolnitrin to pyrrolnitrin 
and requires the involvement of a flavin reductase to provide reduced flavin for 
PrnD from NADPH (figure 1-31).159 Because the substrate for PrnD is not easily 
obtained, a substrate analog pABA was used to investigate the mechanism for 
this arylamine oxidation reaction. In this Rieske N-oxygenase catalyzed oxidation 
reaction, the amine group is first oxidized to a hydroxyl group and then to a 
nitroso group before the formation of the final product with a nitro group (figure 1-
32).160  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-31. Biosynthetic pathway of pyrrolnitrin and mechanism of PrnD 
catalyzed reaction. 
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Figure 1-32. Biosynthetic mechanism of N-oxidazse PrnD. 
 
N-oxidase AurF represents another example involved in the biosynthesis 
of aryl nitro polyketide secondary metabolite aureothin, which is produced by 
Streptomyces thioluteus and exhibits potent antifungal and antitumor activities.161 
The gene cluster for the biosynthesis of aureothin was identified from the 
genome of S. thioluteus and subsequent analysis of this gene cluster showed 
that the PKS was involved in the biosynthesis of aureothin.162 The function of the 
aureothin gene cluster has been determined using gene disruption and 
heterologous expression methodologies. In the aureothin biosynthetic gene 
cluster, the function of AurF was suggested to be an N-oxidase based upon in-
frame deletion results.65 Biochemical experiments further proved the function of 
AurF which can catalyze the oxidation of para-aminobenzoic acid (pABA) to 
para-nitrobenzoic acid (pNBA) through the intermediate para-(hydroxyamino) 
benzoic acid (figure 1-33).163, 164 The two oxidation reactions mediated by PrnD 
and AurF share very similar biosynthetic pathways, but show basically no protein 
sequence similarity with each other. In addition, the mechanisms for these two 
oxidation reactions catalyzed by PrnD and AurF are dramatically different. As 
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mentioned above, PrnD is a Rieske N-oxygenase require an iron-sulfur cluster 
for its activity, whereas AurF is actually a di-nuclear N-oxygenase.163  
 
 
 
Figure 1-33. Biosynthetic pathway of aureothin. 
 
2.2.3 Possible oxidative functions of halogenases in the biosynthesis of aryl 
nitro natural products 
As can be seen from the structures of aryl nitro containing natural 
products, chlorine is often found to coexist with those aryl nitro functional groups 
and introduced into natural products by halogenases. So those identified 
halogenases from the biosynthetic gene clusters can possibly function in the 
oxidation of amino groups to nitro groups. Indeed, some experiments have 
provided some evidence showing the ability of halogenase to  oxidize aryl amine 
groups to aryl nitro groups, however these oxidation reactions actually occurred 
only in extreme or non natural conditions.165, 166 So it is very possible that the N-
oxidation reaction catalyzed by halogenases should not happen in vivo and 
halogenases are not the true N-oxidases.  
 
3. Dissertation aims 
 
3.1 Biosynthesis of pyrrolo[2,1-c] benzodiazepine natural products 
pyrrolo[2,1-c] benzodiazepine natural products represent a very important 
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class of natural products produced by microorganisms. PBD natural products 
exhibit dramatic biologically activities, especially antitumor activity and 
antibacterial activity. To date, a great variety of synthetic benzodiazepine 
containing drugs have been used clinically mainly as anxiolytic, hyptonic, 
anticonvulsant and muscle relaxant, etc. Since microorganisms can produce 
benzodiazepine natural products with dramatic biological activities, it will be very 
interesting and of great significance to study and investigate the biosynthetic 
pathways and mechanisms for benzodiazepine natural products. In the 1970’s, 
the Hurley research group studied the biosynthetic building blocks of 
benzodiazepine natural products, notably anthramycin, tomaymycin and 
sibiramycin, by using isotopic labeling experiments. Benzodiazepine natural 
products have been demonstrated to be derived from three amino acids: 
tryptophan, tyrosine and methionine. But afterwards, very little is known in terms 
of the biosynthesis of microbial benzodiazepine natural products at either the 
genetic level or the biochemical level.  So in this project, we intended to 
investigate the biosynthetic pathways and mechanisms of benzodiazepine 
natural products mainly from the genetic level. In our case, we studied the 
biosynthesis of anthramycin, which is produced by S. refuineus and is the first 
isolated benzodiazepine natural products. Generally the biosynthetic genes for 
natural products produced by bacteria are clustered on the genome, our purpose 
is to identify the biosynthetic gene cluster from the genome of S. refuineus and 
investigate the biosynthetic pathway of anthramycin using genetic methods. The 
identification of anthramycn biosynthetic gene cluster will greatly facilitate the 
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identification of gene clusters for other benzodiazepine natural products and 
pave the way for the biochemical studies of benzodiazepine natural products. In 
the process of studying anthramycin biosynthesis, we developed a new method 
which was able to recombine two partial anthramycin gene clusters into a 
complete anthramycin biosynthetic gene cluster on the same vector. 
Heterologous expression of the anthramycin gene cluster further confirmed the 
function of the identified anthramycin gene cluster and ruled out the possibility 
that genes outside this identified gene cluster were also involved in anthramycin 
biosynthesis.  
 
3.2 Biosynthesis of nitrosugar containing natural products 
 Natural products have been demonstrated to exhibit potent biological 
activities and have been utilized as a great resource for drug discovery. A great 
many natural products, especially those produced by microorganisms, contain 
amino sugars or nitrosugars. The biosynthetic pathways and mechanisms for 
some amino sugars and nitrosugars containing natural products have been 
studied and elucidated in the past twenty years. Among those identified amino 
sugars in natural products, not all amino sugars can be converted to nitrosugars. 
So in the identified nitrosugar biosynthetic gene clusters, there should be some 
oxidases which are responsible for the oxidation of amino sugars to nitrosugars 
in natural products. Before our studies on nitrosugar containing natural products, 
several other research groups studied and investigated the biosynthetic 
mechanisms of aryl nitro groups in natural products. In our this project, we 
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intended to identified the genes coding for the oxidases for the biosynthesis of 
nitro groups in nitrosugar containing natural products from the identified 
biosynthetic gene clusters for nitrosugar containing natural products using 
comparative genomic method. Afterwards, the oxidases proposed for the 
oxidation from amino sugars to nitrosugars were expressed and purified in E. coli. 
The function of the identified oxidases was chacterized using the chemically 
prepared amino sugar substrate.  
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CHAPTER II 
 
BIOSYNTHESIS OF ANTHRAMYCIN FROM STREPTOMYCES REFUINEUS 
 
Introduction 
Anthramycin is a model compound in Pyrrolo[2,1-c] benzodiazepine (PBD) 
class and exhibits potent antitumor and antibacterial activity as well several other 
important biological activities.1, 2 The activities of anthramycin have been 
demonstrated to be due to the irreversible formation of a covalent bond between 
anthramycin and double-stranded DNA. The anthramycin-DNA adduct is able to 
cause the degradation of DNA and further inhibit the synthesis of DNA and RNA 
from their DNA template.3-5 Because of its dramatic biological activities and 
unique mechanism, the anthramycin scaffold has been developed for drug 
discovery and utilized clinically for cancer treatment. The existing problem for 
anthramycin as well as other antitumor compounds being studied in the 
preclinical stage, is the inherent dose-limiting cardiotoxicity for cancer patients, 
preventing the broad applications of anthramyicn and other structurally related 
PBDs in the treatment of cancer.6 “Red/ET cloning system” 
The discovery of anthramycin was reported as early as 1940’s but at that 
time anthramycin was believed to be a protein produced by its producer 
actinomycete Streptomyces refuineus sbsp. Thermotolerans.7 Later, with the 
development of chemical techniques, anthramycin was confirmed to be a small 
molecule rather than a protein. Anthramycin was isolated and purified from the 
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broth of S. refuineus and the chemical structure of anthramycin was solved using 
NMR1.  The total synthesis of anthramycin in 1960s confirmed the chemical 
structure of anthramycin.8 Anthramycin producer S. refuineus is kind of unusual 
in that S. refuineus is a thermotolerant strain and anthramycin is produced at 
47°C. S. refuineus belongs to genus Streptomyces, but interestingly, its 
morphology is very similar to that of E. coli when it is cultured in liquid medium or 
solid medium.  
The biosynthesis of anthramycin has been extensively studied after its 
isolation. The excellent research was mainly accomplished by the Hurley group9, 
10 in the 1970s. For a long time, the elucidation of the anthramycin biosynthetic 
pathway was based mainly on the results of feeding labeled precursors into the 
anthramycin producer S. refuineus. Those feeding studies have provided 
insightful information related to the biosynthesis of anthramycin and made the 
anthramycin biosynthetic pathway much clearer than before. We can also notice 
that there are still many biosynthetic questions remained to be solved, especially 
within the partial biosynthetic pathway of the dehydroproline five-member ring of 
anthramycin and the overall biochemical mechanism for the formation of 
anthramycin.  
After the early research work for anthramycin that had been carried on in 
the Hurley laboratory, there seems to have been little progress in the biosynthetic 
study of anthramycin as well as other PBD natural products. In recent years, the 
anthramycin biosynthetic gene cluster, the first gene cluster for PBD natural 
products, was identified from the genome of anthramycin producer Streptomyces 
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refuineus by our collaborators in Ecopia Bioscience Inc. The identification of 
anthramycin biosynthetic gene cluster greatly facilitates the biosynthetic study of 
PBD compounds at both genetic and biochemical levels.  In our laboratory, we 
mainly study the biosynthesis of anthramycin from the genetic perspective and 
the research work focusing on anthramycin biosynthesis in our laboratory 
includes:  
1) We developed a high-efficient genetic manipulation system suitable for the 
anthramycin producer Strptomyces refuineus via E. coli-Streptomyces 
intergenetic conjugation. Using this mature transformation method, we were able 
to transform plasmids or cosmids containing oriT fragment into S. refuineus and 
manipulate the biosynthetic gene cluster of anthramycin as designed.  
2) We disrupted several key genes in the anthramycin gene cluster: orf12, 
orf19, NRPS (orf21 & orf22) to confirm that the identified DNA locus on the 
genome of anthramycin producer S. refuineus was indeed the anthramycin 
biosynthetic gene cluster. For the disruption of our target genes, we utilized a 
new gene disruption method, a “Red/ET cloning system”11, to mutate certain 
genes in the anthramycin gene cluster.  
3) Additionally, we determined the boundaries of anthramycin biosynthetic 
gene cluster using the “Red/ET cloning system”. We mutated five genes: orfAS10, 
orf1, orf23, orf24 and orfS11 in the boundary regions of the anthramycin gene 
cluster and demonstrated that orf1 and orf25 were the configurations boundaries 
of anthramycin biosynthetic gene cluster. 
4) We elucidated a partial anthramycin biosynthetic pathway: the pathway for 
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intermediate 3-hydroxy-4-methylanthranilic acid. Since we had the mutant strains 
for several disrupted genes in anthramycin gene cluster and some possible 
intermediates, we did chemical complementation experiments to elucidate this 
partial anthramycin biosynthetic pathway.  
After the identification and functional determination of the anthramycin 
biosynthetic gene cluster, several other biosynthetic gene clusters of 
benzodiazepine natural products have also been reported. In 2008, the 
biosynthetic gene cluster for diazepinomicin/ECO-460112(figure 2-01), a novel 
farnesylated dibenzodiazepinone currently in clinical trials for the treatment of 
brain, breast, prostate, and pancreatic tumors, was identified from Micromospora 
sp. 046-ECO11.13, 14 Labeled feeding experiments have been carried out to 
elucidate the diazepinomicin biosynthetic pathway which is proposed to be 
derived from 3-hydroxyanthranilic acid and 3-amino-5-hydroxybenzoic acid.12  
The biosynthetic gene cluster of lincomycin, a natural product biosynthetically 
related to anthramycin, was also found from its producer Streptomyces 
lincolnensis in 2008.15 The function of this lincomycin gene cluster was confirmed 
by using heterologous expression in Streptomyces coelicolor. Elucidation and 
comparison of the identified biosynthetic pathways of PBDs and structurally 
related natural products may provide further insights into our understanding of 
their biosynthetic mechanisms. Manipulations of benzodiazepines biosynthetic 
gene clusters on the genome of their producers can possibly increase the 
production of desired natural products or produce novel benzodiazepines with 
superior or novel biological activities.  
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Figure 2-01. Biosynthetic building blocks of diazepinomicin/ECO-4601. 
 
 
Results and discussion 
1. Identification of anthramycin biosynthetic gene cluster from 
Streptomyces refuineus 
Using isotopic labeling experiments, Hurley et al. proposed that 
anthramycin was derived from two halves, each derived by oxidative ring opening 
of an aromatic amino acid followed by subsequent biosynthetic tailoring steps. 
The 4-methyl-3-hydroxyanthranilic acid half of anthramycin was proposed to be 
derived from tryptophan via the primary metabolic kynurenine pathway followed 
by S-adenosylmethionine dependent aromatic C-methylation. The 
‘‘dehydroproline acrylamide’’ moiety was derived from L-tyrosine via the oxidative 
ring opening of intermediate DOPA. 
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The identification of anthramycin biosynthetic gene cluster was 
accomplished by Ecopia Biosciences Inc. In this study, the DNA locus for 
biosynthesis of anthramycin was identified using a rapid genome-scanning 
approach.  
Briefly, a two-tiered genomic DNA library (of 1.5–3 kb and 30–50 kb 
fragments) was constructed from sonically and enzymatically sheared high-
molecular-weight DNA, respectively, isolated from Streptomyces refuineus sbsp. 
thermotolerans. The short insert library was cloned into a pBluescript SK+ 
derivative. A total of 486 genomic sequence tags (GSTs) were generated by 
sequencing randomly selected clones. Clones were analyzed for sequence 
similarity to secondary metabolic genes in the NCBI nonredundant protein 
database. In this manner, a single GST was identified containing sequence 
similarity to the predicted requisite NRPS. An 864-member cosmid insert library, 
corresponding to approximately 3- to 4-fold coverage, was created from the large 
fragment DNA. The NRPS GST was labeled and used as colony-hybridization 
probe for the identification of anthramycin cluster containing cosmid candidates. 
The fragments on those cosmid candidates were sequenced by a short-gun 
sequencing approach.  
Two cosmids 024CA and 024CO, were identified, each containing portions 
of the anthramycin biosynthetic gene cluster with an approximate 10 kb overlap 
DNA region. The identified DNA locus appeared to harbor the complete gene 
cluster for the biosynthesis of anthramycin (figure 2-02). Sequence analysis 
reveals that the open reading frame anthramycin cluster contains genes 
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consistent with the biosynthesis of the two halves of anthramycin: 4 methyl-3-
hydroxyanthranilic acid and a ‘‘dehydroproline acrylamide’’ moiety. These non-
proteinogenic amino acid precursors are condensed by a two-module 
nonribosomal peptide synthetase (NRPS) terminated by a reductase domain, 
consistent with the final hemiaminal oxidation state of anthramycin. The 
boundaries of the gene cluster were deduced by comparative genomics. 
 
 
 
 
Figure 2-02. DNA locus that contains proposed anthramycin biosynthetic gene 
cluster. 
 
 
The functions of the identified genes in the biosynthetic gene cluster of 
anthramycin were proposed by comparing their protein sequences with the 
sequences deposited in the National Center for Biotechnology Information (NCBI) 
protein database. In the identified anthramycin biosynthetic gene cluster, 25 
genes are proposed to be involved in the biosynthesis of anthramycin and 
consist of genes for 4-methyl-3-hydroxy-anthranilic acid biosynthesis, genes for 
the biosynthesis of the pyrrolylacrylamide moiety, a bimodular NRPS system as 
well as gene candidates for regulation, resistance, and transport (table 2-01). 
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Table 2-01. Open Reading Frame Analysis for Anthramycin Gene Cluster from 
Streptomyces refuineus 
ORF #AA GenBank Homology % Identity/Similarity Proposed Function 
AS10 138 AAU19321.1 46/68 unknown, hypothetical protein 
1 624 BAB12569.1 57/68 amidotransferase 
2 500 CAD30313.1  aldehyde dehydrogease 
3 354 EAO60654.1 50/65 alcohol dehydrogenase 
4 410 CAJ23858.1 49/63 Cytochrome P-450 hydroxylase 
5 352 487713 79/87 lmbA, methyltranferase 
6 621 CAA55746.1 73/80 lmbW, unknown function 
7 487 ABF90321.1 38/54 FAD oxidoreductase 
8 764 AAL06654.1 59/75 drug-resistence pump 
9 256 CAB55527.1 27/40 putative hydroxylase/glyoxylase 
10 377 EAL16816.1 41/66 transporter 
11 89 – – none 
12 169 CAA55747.1 48/63 lmbB1, L-DOPA 2,3-dioxygenase 
13 302 CAA55748.1 42/54 lmbB2, L-tyrosine 3-hydroxylase 
14 297 CAA55772.1 50/63 lmbY, unk. lincomycin biosynth. 
15 276 CAA55771.1 34/41 lmbX, unk. lincomycin biosynth. 
16 413 42543461 37/57 kynureninase 
17 261 4753870 37/52 tryptophan 2,3-dioxygenase 
18 58 – – none 
19 348 37542638 43/63 aromatic C-methyltransferase 
20 296 EAU10758.1 36/49 aryl formamidase 
21 600 CAD92850.1 35/51 NRPS 
22 1146 ABF90459.1 32/46 NRPS 
23 500 ABF39686.1 32/49 kynurenine 3-monooxygenase 
24 475 ABF87356.1 36/50 flavin-containing oxidoreductase 
25 273 BAC79018.1 46/64 repressor-response regulator 
S11 174 BAC69182.1 63/68 Zn-dependent hydrolase 
S12 199 EAU12469.1 31/53 unknown, hypothetical protein 
 
 
4-methyl-3-hydroxyanthranilic acid biosynthesis in anthramycin 
Several genes putatively assigned for the biosynthesis of 4-methyl-3-
hydroxyanthranilic acid are comprised of homologs of primary metabolic genes 
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involved in 3-hydroxyanthranilic acid biosynthesis (orf16, orf17, orf20 and orf23) 
as shown in table 2-01. These four genes are proposed to be involved in the 
biosynthesis of 3-hydroxyanthranilic acid and show high similarity with the genes 
in the biosynthetic gene clusters of other secondary metabolites containing the 3-
hydroxyanthranilic acid structural unit, for example from the gene cluster of 
actinomycin produced by various Streptomyces.18 Notably, the chemical structure 
of actinomycin contains a building block of 4-methyl-3-hydroxyanthranilic acid. So 
anthramycin and actinomycin very possibly share the same or similar 
biosynthetic pathway for the formation of 4-methyl-3-hydroxyanthranilic acid or 3-
hydroxyanthranilic acid intermediate. The proposed biosynthetic pathway for 3-
hydroxyanthranilic acid that is derived from L-tryptophan and requires the 
modifications by orf16, orf17, orf20 and orf23 in anthramycin biosynthetic gene 
cluster is shown in figure 2-03. The existence of a C-methyl group on the 
anthranilate A-ring suggests that a C-methyltransferase should be encoded by a 
gene inside the anthramycin biosynthetic gene cluster. Actually, there are two 
genes putatively encoding methyltransferases in the anthramycin biosynthetic 
gene cluster, orf5 and orf19. Methyltransferase ORF5 is probably involved in the 
biosynthesis of dehydroproline acrylamide building block and addition of the 
unique C1 unit because it shows high sequence similarity with another C-
methyltransferase in the biosynthetic gene cluster of lincomycin which shares a 
similar dehydroproline structure.19 So we speculate that ORF19 should be the C-
methyltransferase to append the aryl methyl group. Orf24 is proposed to encode 
a flavin-dependent oxidase or an amine oxidase and seems to not be involved in 
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the biosynthesis of dehydroproline. In the identified DNA locus, orf24 is clustered 
with orf23, a gene for the biosynthesis of 3-hydroxyanthranilic acid. Thus, orf24 is 
possibly related to the biosynthesis of 3-hydroxyanthranilic acid but the precise 
function of this gene has not been well investigated.  
 
 
 
 
 
 
 
 
Figure 2-03. Proposed partial biosynthetic pathway for 3-hydroxy-4-
methylanthranilic acid. 
 
 
Dehydroproline acrylamide biosynthesis in anthramycin 
The dehydroproline acrylamide building block present in anthramycin is 
very similar to the 4-propyl-4,5-dehydroproline structure from lincomycin A, a 
secondary metabolite produced by Strptomyces lincolnensis.19 Seven genes 
(orf1, orf2, orf3, orf4, orf5, orf12 and orf13) in anthramycin biosynthetic gene 
cluster show high sequence similarities with the genes identified from lincomycin 
gene cluster. Feeding experiments have demonstrated that the dehydroproline 
building blocks in anthramycin and lincomycin A are derived from L-tyrosine and 
the terminal C-1 carbon atom in the side chain is provided by methionine.20 The 
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above seven genes can be assigned to be involved in the biosynthetic pathway 
for the unique dehydroproline acrylamide intermediate after the analysis of 
anthramycin and lincomycin biosynthetic gene clusters. A proposed biosynthetic 
pathway for dehydroproline acrylamide in anthramycin is shown in figure 2-04. 
 
 
 
 
 
 
 
 
 
 
Figure 2-04. Proposed biosynthetic pathways of dehydroproline subunits for 
anthramycin, sibiromycin,tomaymycin and lincomycin.  
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interesting portions in anthramycin biosynthesis. Previous incorporation 
experiments have provided evidences the biosynthetic pathway for the formation 
of the dehydroproline acryamide in anthramycin. Unfortunately, very little is 
known about this partial anthramycin biosynthetic pathway at either the genetic 
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from anthramycin gene cluster) in lincomycin biosynthetic gene cluster has been 
reconstituted in vitro and demonstrated to be a Fe2+ dependent L-DOPA 2,3-
dioxygenase which is responsible for the C5-C6 cleavage in L-DOPA.21 The 
functions of other genes proposed to be involved in the dehydroproline 
biosynthetic pathway have not been characterized and need further investigation.   
 
Nonribosomal peptide synthase in anthramycin biosynthesis 
4-methyl-3-hydroxyanthranilic acid and dehydroproline acrylamide are two 
potential precursors of anthramycin. The biosynthetic genes of these two 
compounds can be identified within anthramycin biosynthetic gene cluster. NRPS 
has been shown to be a common paradigm system for the biosynthesis of amide 
bonds in structural diverse small peptides isolated from bacteria and fungi. The 
anthramycin biosynthetic gene cluster contains two genes encoding NRPS, 
which is probably responsible for the amide bond formation of above two 
intermediates. Orf21 encodes an adenylation domain (A domain) and a 
thioesterification domain (T domain). Orf22 encodes a condensation domain (C 
domain), an A domain and a T domain as well as a putative reduction domain 
(Re domain). Notably, the existence of an unusual C-terminal reductase domain 
in the second module suggests that the release of anthramycin from 
magasynthetase NRPS is accomplished by the reduction of the dipeptide 
attached to NRPS instead of a direct hydrolysis of this dipeptide by the T domain 
in ORF22 as evidenced by BLAST homology of C-terminal region to NADH 
binding motifs (figure 2-05). This reductase domain can also be identified in other 
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NRPS magasynthetases from the biosynthetic gene clusters of saframycin, 
myxochelin, nostocyclo peptide and equistin.22-25 A similar reduction reaction 
before the release from NRPS is also required for the biosynthesis of those 
natural products. Another unusual aspect of the NRPS for anthramycin 
biosynthesis is the peptide sequences of A domains in the two modules of the 
NRPS, which show relative low similarity with other known A domains, especially 
the A domain that has been previous demonstrated to activate  4 methyl-3-
hydroxyanthranilic acid in the biosynthesis of actinomycin.26 
 
 
 
 
 
 
 
 
 
 
Figure 2-05. Nonribosomal Assembly and Reductive Release of Anthramycin. 
 
Resistance and regulation 
In the anthramycin biosynthetic gene cluster, orf8 shows 59% identity to 
resistance gene DrrC in the daunorubicin gene cluster27 and orf10 is a 
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gene clusters. So orf8 and orf10 are probably the components of the resistance 
system for anthramycin producer S. refuineus. Orf25 is the only gene in the 
anthramycin gene cluster that encodes an amino acid sequence with similarity to 
response regulators for other natural products, suggesting orf25 may play a 
significant  important role in the regulation of anthramycin biosynthesis.28  
 
2. Functional determination of anthramycin biosynthetic gene cluster 
After the identification of the DNA locus potentially harboring the 
anthramycin biosynthetic gene cluster from the genome of Streptomyces 
refuineus, the function of the identified gene cluster needed to be characterized 
before further genetic and biochemical studies for anthramycin could be 
performed.  
Generally a very straightforward method for determining the function of a 
natural product biosynthetic gene cluster is to disrupt several key genes inside 
this gene cluster. If the production of a natural product is completely abolished 
after the disruption of a gene or a DNA fragment in the identified gene cluster, 
then the function of this gene cluster can be determined and assigned to the 
natural product biosynthetic gene cluster.29 Subsequently, genetic and chemical 
complementation can also be utilized to further confirm the function of a natural 
product biosynthetic gene cluster by reintroducing the complete genes into 
mutant strains.  
To mutate target genes in a natural product biosynthetic gene cluster 
within a genome, a suitable genetic manipulation system needs to be established 
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for a producer strain. Since more than 70% of antibiotics that have been 
discovered so far are produced by Streptomcyes30, tremendous efforts have 
been devoted to the development of genetic system for various Streptomyces 
strains in the past forty years. Three main methods have been employed for the 
transformation of DNA vectors or DNA fragments into Streptomyces strains: 
polyethylene glycol induced protoplast preparation, electroporation and E. coli-
Streptomyces intergenetic conjugation.31 The first two methods have been 
proven to be laborious and the transformation efficiency can not be guaranteed 
for all Streptomyces strains. E. coli-Streptomyces conjugation is a relative new 
transformation method that has been widely used for the genetic study of 
Streptomyces because it can be applied to a great variety of Streptomyces 
strains and exhibits higher efficiency for DNA transformation.32, 33  
In our laboratory, we have successfully developed a genetic manipulation 
system for the anthramycin producer Streptomyces refuineus based on E. coli-
Streptomyces conjugation.  We were able to transform DNA vectors of different 
sizes from E. coli to S. refuineus with very high efficiency. E. coli 
ET12567/pUZ8002 was chosen as the donor strain for conjugation because it 
contains a large plasmid pUZ8002 which is able to mobilize DNA vectors 
containing oriT fragment to Streptomyces.31 The establishment of a genetic 
manipulation system by using the conjugation method greatly facilitated the 
subsequent gene mutations in anthramycin biosynthetic gene cluster from S. 
refuineus.34  
Traditionally, to mutate a single gene or a DNA fragment inside a natural 
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product biosynthetic gene cluster on the genome of its producer, a selective 
marker is put inside two homologous sequences from both sides of the target 
gene and this DNA fragment is cloned into a suitable plasmid followed by the 
transformation of this recombinant plasmid into the natural product producer. 
Because of the existence of homologous sequences between the genome and 
the DNA fragment on the plasmid, recombination can occur between homologous 
sequences and the target gene will be replaced by the selectable marker.35  
 In 2000, a new gene mutation method called “Red/ET cloning system”for 
the efficient disruption of biosynthetic genes in Streptomyces was reported by 
researchers from John Innes Center in England.11 This new approach is based 
on the discovery that in the presence of Red α (exo), Red β (bet) and Red γ (gam) 
proteins of phage λ, recombination can occur between a target gene and a 
selectable marker with homologous nucleotide sequence as few as 40 bp on 
both sides, resulting in the replacement of the target gene by a selectable 
marker.36-40 In this manner, a target gene in a biosynthetic gene cluster which has 
been cloned into a vector such as a cosmid or fosmid can be replaced. 
Subsequently, the vector containing a partial biosynthetic gene cluster with a 
target gene disruption is transformed into the natural product producer strain. 
There are generally more than 10 kb homologous sequences on both sides of a 
target gene, therefore recombination efficiency will be greatly increased using 
this approach, compared with the traditional gene disruption method as 
mentioned above. Dr. Keith F. Chater kindly provided us with this “Red/ET 
cloning system” by which we were able to develop the gene disruption method 
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for anthramycin biosynthetic genes in S. refuineus (figure 2-06).  
 
 
 
 
 
 
Figure 2-06. Gene disruption strategy in “Red/ET cloning system” (copyright of 
John Innes Center, UK).  
 
 In order to determine the function of this cloned DNA locus to be 
anthramycin biosynthetic gene cluster, we decided to mutate several key genes 
in this DNA locus. If anthramycin production could not be detected after the 
disruption of these genes, then this gene cluster could be assigned as 
anthramycin biosynthetic gene cluster.  
 We first disrupted a proposed essential component of the anthramycin 
gene cluster, orf21 & orf22 which encode the NRPS proposed to be responsible 
for the assembly of two intermediates to yield anthramycin. We cloned the 
apramycin resistance gene acc(3)IV from plasmid pIJ773 and about 40 bp 
homologous DNA sequences were added on both sides of  this selectable 
marker via designed PCR primers. Then the cloned apramycin resistance gene 
and cosmid 024OCA containing the partial anthramycin biosynthetic gene cluster 
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were transformed into E. coli BW25113 harboring the plasmid pIJ790 expresses 
the proteins to facilitate DNA homologous recombination. After the induction of L-
arabinose, recombination occurred between the homologous sequences of PCR 
products and cosmid 024CA, resulting in the replacement of orf21 & orf22 by the 
apramycin resistance gene on the partial anthramycin gene cluster in cosmid 
024CA. Subsequently, this recombinant cosmid was transformed into 
anthramycin producer S. refuineus and the target genes orf21 & orf22 were 
replaced by apramycin resistance gene on the genome of S. refuineus. Correct 
double crossover mutant stains were selected for an apramycin resistance (AprR) 
and kanamycin sensitive (KanS) phenotype (figure 2-07).  
 
 
 
 
 
 
 
 
 
Figure 2-07. Anthramycin biosynthetic gene cluster (a), NRPS (orf21&orf22) 
mutant strain (b), orf12 mutant strain (c) and orf19 mutant strain (d).  
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 Following the gene disruption protocol for orf21 & orf22, we utilized 
apramycin resistance gene to replace orf12 which was proposed to encode an L-
DOPA-dioxygenase involved in the biosynthesis of dehydroproline acrylamide 
and orf19 which was proposed to code for the C-methyltransferase for the C-
methylation on anthranilate aromatic A-ring, respectively. Corresponding mutant 
strains for these two genes were selected based on AprR and KanS phenotype 
(figure 2-07).  
 The thusly obtained mutant strains for orf12, orf19 and NRPS (orf21&orf22) 
were confirmed by PCR using primers from outside the target genes and inside 
apramycin resistance gene. Subsequently, the mutant strains were subject to 
liquid culture for the isolation of anthramycin. The detection of anthramycin from 
these three mutant strains was carried out by using HPLC-MS analysis. After 
deletion of orf12, orf19 and NRPS (orf21&orf22), no anthramycin could be 
detected in the fermentation broth for any of these three mutant strains, with the 
isolated anthramycin from its producer S. refuineus under the same culture 
conditions as a positive control (figure 2-08).  
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Figure 2-08. Anthramycin production from S. refuineus(up left), orf12 mutant (up 
right), orf19 mutant (down left) and orf21&orf22 mutant (down right).  
 
The above anthramycin abolishment results from the anthramycin mutant 
strains of orf12, orf19 and NRPS (orf21&orf22) confirmed that the DNA locus we 
identified from the genome of S. refuineus was indeed the anthramycin gene 
cluster and responsible for the biosynthesis of anthramycin.  
In summary, a genomic DNA library of anthramycin producer 
Streptomyces refuineus was constructed and the DNA locus proposed to contain 
the anthramycin biosynthetic gene cluster was identified from the genome of S. 
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refuineus. From the genomic DNA library, two cosmids containing the potential 
anthramycin biosynthetic gene cluster were sequenced and sequence analysis 
suggested that this DNA locus probably harbored the complete anthramycin 
biosynthetic gene cluster with the biosynthetic genes for intermediates 4-methyl-
3-hydroxyanthranilic acid and dehydroproline acrylamide as well as NRPS to 
assemble these two intermediates into anthramycin. A high-efficient genetic 
manipulation system for anthramycin producer S. refuineus was developed in our 
laboratory. We disrupted several key genes (orf12, orf19 and NRPS 
(orf21&orf22)) in this proposed anthramycin gene cluster using a new gene 
disruption method, “Red/ET cloning system”. The gene disruption results 
confirmed the function of this DNA locus to be the anthramycin biosynthetic gene 
cluster.  
 
3. Boundaries determination of anthramycin biosynthetic gene cluster 
A series of gene disruption experiments that have been carried out in our 
laboratory providing supportive evidence for the DNA locus identified from the 
genome of S. refuineus as the anthramycin biosynthetic gene cluster. Previous 
sequence analysis of this anthramycin biosynthetic gene cluster, after comparing 
the protein sequences against the protein database in NCBI, suggested that the 
anthramycin biosynthetic gene cluster containing 25 genes was proposed to start 
at orf1 and conclude at orf25.  
Biosynthetic genes for natural products produced by bacteria are generally 
clustered together with very few exceptions. Anthramycin biosynthetic genes 
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were also proposed to be clustered on the genome based upon the sequence 
analysis of the DNA locus containing anthramycin gene cluster, with orf1 and 
orf25 proposed to be the boundaries of this gene cluster base on the BLAST 
results from NCBI. Since we have already successfully established a genetic 
manipulation system for anthramycin producer S. refuineus and are able to utilize 
the “Red/ET cloning system” to mutate target genes as designed, the boundaries 
of anthramycin gene cluster can also be identified by gene inactivation studies. 
The biosynthetic genes in the proposed boundary regions of the anthramycin 
gene cluster can be replaced separately using “Red/ET cloning system”. After 
mutation of individual genes required for the biosynthesis of anthramycin, the 
production of anthramycin will be completely abolished in the mutant strains. 
Correspondingly, the mutation of genes not essential to anthramycin biosynthesis 
will not have effect on the biosynthesis of anthramycin and anthramycin should 
still be produced by these mutant strains. Using this strategy, we should be able 
to determine the boundaries on both sides of anthramycin biosynthetic gene 
cluster by analyzing the results of anthramycin production from the mutant strains 
we generate.  
Orf1 was proposed to be the left boundary of the anthramycin biosynthetic 
gene cluster. In order to determine the left boundary of this gene cluster, we 
disrupted orf1 and orfAS10 which resides next to orf1 and right outside the 
proposed anthramycin gene cluster. Similar to the gene disruptions we achieved 
before, we utilized the apramycin resistance gene to replace orfAS10 and orf1 
separately through double crossover homologous recombination on the genome. 
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Corresponding knockout strains for these separate genes were selected based 
on AprR and KanS phenotype and further confirmed by PCR using primers from 
outside the target genes and inside the apramycin resistance gene (figure 2-09). 
HPLC-MS and bioactivity were utilized to detect the production of anthramycin 
from the fermentation broth of orfAS10 and orf1 mutation strains with 
anthramycin from its producer S. refuineus as a positive control. Orf1 was 
proposed to code for an amidotransferase responsible for the formation of the 
unique carboylamide structure in dehydroproline acrylamide intermediate of 
anthramycin. After the deletion of orf1 from the genome of S. refuineus, the 
production of anthramycin was completely abolished and no anthramycin 
production could be detected in the extracts from fermentation broth of orf1 
mutant strain, suggesting that orf1 is a key gene related to anthramycin 
biosynthesis. Whereas the disruption of orfAS10, a gene encoding a protein with 
unknown function, did not affect the production of anthramycin and anthramycin 
could still be detected from the fermentation medium of the orfAS10 mutant strain, 
indicating orfAS10 is not related to anthramycin biosynthesis. These results 
demonstrated that orf1 was the left boundary of anthramycin biosynthetic gene 
cluster and played a very important role in the biosynthesis of anthramycin, which 
was consistent with our prediction based on the sequence analysis of the DNA 
locus containing anthramycin gene cluster (figure 2-10).  
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Figure 2-09. Anthramycin biosynthetic gene cluster (a), orfAS10 mutant strain (b) 
and orf1 mutant strain (c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-10. Anthramycin production from orfAS10 mutant  and orf1 mutant. 
 
Similarly, to determine the right boundary of anthramycin biosynthetic 
gene cluster, we also disrupted several genes (orf23, orf24 and orfS11) in this 
boundary region. Our prediction, after the analysis of anthramycin gene cluster, 
was that orf25 encoding a regulatory gene should be the right boundary and the 
genes upstream of orf25 should be related to anthramycin biosynthesis and 
within anthramycin biosynthetic gene cluster. However, the disruption of 
regulatory gene orf25 should either up-regulate or down-regulate the production 
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of anthramycin. So the disruption result of orf25 can not provide direct evidence 
in terms of whether this gene is involved in anthramycin biosynthesis. Since orf25 
is the only regulatory gene in this DNA locus, it is very possible that orf25 plays a 
very important regulatory role in the production of anthramycin. To characterize 
the functions of biosynthetic genes on both sides of orf25, we mutated these 
three genes separately using the previous developed gene disruption method we 
have developed in our laboratory (figure 02-11). The fermentation results 
demonstrated our prediction that orf23 and orf24 were involved in the 
biosynthesis of anthramycin and orfS10 was not related to anthramycin 
production because the mutant strains of orf23 and orf24 failed to produce 
anthramycin whereas anthramycin could still be detected from orfS10 mutant 
strains. Based on gene disruption results together with sequence information of 
anthramycin biosynthetic gene cluster, orf25 was determined to be the right 
boundary of anthramycin gene cluster from S. refuineus (figure 2-12).  
 
 
 
 
 
 
Figure 2-11. Anthramycin biosynthetic gene cluster (a), orfS11 mutant strain (b) 
and orf23 mutant strain (c) and orf24 mutant strain (d). 
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Figure 2-12. Anthramycin production from S. refuineus, orfS11 mutant, orf23 
mutant and orf24 mutant.  
 
In summary, gene disruptions were carried out in our laboratory to 
determine the boundaries of anthramycin biosynthetic gene cluster using a new 
gene disruption method, “Red/ET cloning system”, for anthramycin producer S. 
refuineus.  The gene mutation results of orfAS11, orf1, orf23, orf24 and orfS10 in 
the boundary regions of anthramycin gene cluster together with DNA sequence 
information demonstrated that orf1 and orf25 were the boundaries of the 
anthramycin gene cluster and strongly supported our previous prediction derived 
from the sequence analysis of the anthramycin gene cluster.  
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4. Partial elucidation of anthramycin biosynthetic pathways 
The anthramycin biosynthetic gene cluster that has been identified from 
the genome of S. refuineus putatively contains the genes necessary for the 
biosynthesis of 3-hydroxyanthranilic acid. ORF17 shows high similarity to 
tryptophan 2,3-dioxygenases and probably can catalyze the oxidation of the 
double bond in the five member-ring of tryptophan to yield N-formylkynurenine. 
ORF20 probably catalyzes the next biosynthetic step in which N-
formylkynurenine is reduced to L-kynurenine and the aldehyde group is removed. 
ORF23 which is probably a kynurenine 3-monooxygenase can introduce a 
hydroxyl group to the aromatic ring and yield 3-hydroxykynurenine. ORF16 is a 
kynureninase and probably responsible for the transformation from 3-
hydroxykynurenine to 3-hydroxy-anthranilic acid with L-alanine as a byproduct. 
ORF19 is proposed to be C-methyltransferase for C-methylation of the 
anthranilate aromatic A-ring to yield 3-hydroxy-4-methylanthranilic acid (table 2-
01).  
 In the anthramycin biosynthetic gene cluster, orf24 is clustered with orf23 
and previously we have demonstrated orf24 is involved in the biosynthesis of 
anthramycin. Protein sequence analysis has shown that ORF24 is proposed to 
encode a flavin-dependent oxidoreductase or an amine oxidase but seems not to 
be involved in the biosynthesis of dehydroproline. So we speculated that orf24 is 
possibly related to the biosynthesis of 3-hydroxy-anthranilic acid.  
In our previous studies to determine the function and boundaries of 
anthramycin biosynthetic gene cluster, we generated several anthramycin mutant 
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strains, especially orf23 and orf19, which were proposed to be involved in the 
biosynthesis of 3-hydroxy-anthranilic acid. The intermediates in 3-hydroxy-
anthranilic acid biosynthetic pathway are either commercially available or can be 
prepared by chemical synthesis in our laboratory. We are then able to feed these 
intermediates to orf23 and orf19 mutant strains to chemically complement the 
function of these genes. Since orf24 is also potentially involved in 3-hydroxy-
anthranilic acid biosynthesis and we have the orf24 mutant strain on hand, we 
can feed these possible intermediates into the fermentation broth of the orf24 
mutant strain and determine whether they could chemically complement 
anthramycin production from mutant strains.  
Chemical complementation results strongly suggested that 3-hydroxy-
anthranilic acid was a late stage intermediate for anthramycin, because it could 
be fed into gene knockout strains and lead to the formation of a 
demethylanthramycin. A related case study is diazepinomicin/ECO-4601 which 
shares a similar aromatic A-ring with anthramycin. Feeding experiments have 
already demonstrated that 3-hydroxy-anthranilic acid is an important precursor of 
diazepinomicin because 4,6-D2-3-hydroxyanthranilic acid could be successfully 
incorporated into diazepinomicin. The feeding studies of 3-hydroxyanthranilic 
acid into diazepinomicin are consistence with our chemical complementation 
results for the restoration of anthramycin in orf19 and orf23 mutant strains by 3-
hydroxyanthranilic acid (table 2-02).  
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Figure 2-13. Proposed precursors and biosynthetic pathways for 3-hydroxyl-4-
methylanthranilic acid.  
 
 
Table 2-02. Chemical complementary results to elucidate 3-hydroxy-4-
methylanthranilic acid biosynthetic pathway (A: L-kynurenine, B: 3-
hydroxykynurenine, C: 3-hydroxy-anthranilic acid, D: 3-hydroxy-4-
methylanthranilic acid).  
                                A                            B                              C                                D                        
ORF Th Obs Th Obs Th Obs Th Obs 
19 - - 302 - 302 302 316 - 
23 - - 302 
316 
302 
316 
302 302 316 - 
 
24 302 
316 
- 302 
316 
- 
316 
302 302 316 - 
 
 
 Orf23 was proposed to the oxidase take part in the biosynthesis of 3-
hydroxyanthranilic acid with 3-hydroxykynurenine as its direct product. After we 
fed 3-hydroxykynurenine into orf23 mutant strain, anthramycin production could 
be restored. These chemical complementation results confirmed that orf23 was 
involved in the biosynthesis of anthramycin with 3-hydroxykynurenine as the 
direct product of orf23 and precursor of anthramycin. 
 Orf19 was proposed to be the methyltransferase for the C-methylation of 
anthranilate aromatic A-ring, but we could not detect anthramycin production 
from the fermentation broth of orf23 and orf19 mutant strains after feeding 3-
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hydroxy-4-methylanthranilic acid into these two mutant strains. Based on the 
isotopic feeding studies in the Dr. Hurley lab, 3-hydroxy-4-methylanthranilic acid 
was a very possible intermediate for both sibiromycin and anthramycin.  The 
results of these experiments were contradictory. However, it has also been 
demonstrated that actually 3-hydroxy-4-methylanthranilic acid was not 
incorporated into the anthramycin producer S. refuineus probably because of the 
lack of permeability for this compound with S. refuineus. Our feeding results were 
consistent with previous labeling studies for anthramycin biosynthesis. Despite 
the fact that 3-hydroxy-4-methylanthranilic acid could not restore anthramycin 
production for orf23 and orf19 mutant strains, 3-hydroxy-4-methylanthranilic acid 
could not be definitely denied as an important intermediate for anthramycin 
biosynthesis and in vitro biochemical experiments might possibly determine the 
function of ORF19 as a C-methyltransferase.  
Protein sequence analysis has shown that orf24 codes for a flavin-
dependent oxidoreductase. Orf17, orf20, orf23 and orf16 seem to be sufficient for 
the biosynthesis of intermediate 3-hydroxyanthranilic acid. However, our feeding 
studies have shown that both 3-hydroxyanthranilic acid and 3-hydroxykynurenine 
could chemically complement demethylanthramycin or anthramycin production 
from orf24 mutant strain, which was consistent with the chemical 
complementation results for orf23 mutant strain. Based on sequence analysis of 
the genes in the anthramycin biosynthetic gene cluster, we still prefer that the 
hydrolase orf20 which encodes an aryl formamidase, rather than orf24, is 
involved in 3-hydroxyanthranilic acid biosynthesis. Since orf23 and orf24 are 
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clustered in anthramycin gene cluster, the disruption of orf24 may affect the 
function of orf23, very possibly at the genetic level. The function of 
oxidereductase ORF24 can not be definitely assigned to be related to 3-
hydroxyanthranilic acid biosynthesis and needs further investigation.  
We also performed chemical complementation by feeding a possible 
intermediate N-formylkynurenine into above three mutant strains. N-
formylkynurenine failed to lead to anthramycin restoration, which was as 
expected.  The reason for this is probably that N-formylkynurenine actually 
occurs prior to the biosynthetic steps mediated by ORF23 and ORF19 (figure 2-
13 & table 2-02).  
In summary, the biosynthesis of 3-hydroxy-4-methylanthranilic acid of 
anthramycin has been demonstrated to be derived from kynurenine pathway. 3-
hydroxy-anthranilic acid is a key intermediate for anthramycin biosynthesis. 
ORF23 can catalyze the conversion from L-kynurenine to 3-hydroxykynurenine. 
Whether ORF24 is related to the biosynthesis of 3-hydroxy-4-methylanthranilic 
acid and when the timing of C-methylation on this aromatic group remains 
unresolved of this time. On the basis of chemical complementary results, the 
biosynthetic pathway for 3-hydroxy-4-methylanthranilic acid is provided in figure 
2-14.  
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Figure 2-14. Proposed partial biosynthetic pathway for 3-hydroxy-4-
methylanthranilic acid on the base of chemical complementary results.  
 
 
 
Materials and methods 
Bacterial Strains and Culture Conditions 
Streptomyces refuineus var. thermotolerans (NRRL 3143) and its 
derivatives were maintained and grown on either ISP4 medium or TSB medium 
with appropriate antibiotics at 37°C. For anthramycin production, S. refuineus 
and its derivatives were cultured in production medium (1% corn starch, 2% 
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peptonized milk, and 0.3% yeast extract at pH 7.0) at 47°C. Bacillus sp. TA 
(NRRL B-3167) was cultured in nutrient agar and used as a test organism for the 
antibacterial activity of S. refuineus and its derivatives. DH10B (Invitrogen) 
served as host for S. refuineus genomic library construction. E. coli BW25113 
containing plasmid pIJ790 was used for targeted gene disruption in S. refuineus. 
E. coli ET12567 containing the RP4 derivative pUZ8002 was used for 
intergeneric conjugation between E. coli and S. refuineus. E. coli strains were 
grown in LB medium supplemented with appropriate antibiotics for selection of 
plasmids.  
Plasmids and General DNA Procedures  
SuperCos-1 derivatives were used to construct genomic libraries of S. 
refuineus. DNA isolation and manipulation, cosmid preparation, and gel 
electrophoresis were conducted according to standard methods. Cosmid DNA 
was isolated from E. coli strains by using Qiagen miniprep kits. Isolation of DNA 
fragments from agarose was carried out by using Qiagen gel extraction kit. 
Genomic DNA from S. refuineus and its derivatives were isolated by using 
Wizard genomic DNA purification kit (Promega). 
Genomic Sampling Library Construction and Screening 
SuperCos-1 derivatives were used to construct genomic libraries of S. 
refuineus. High molecular weight DNA was isolated by established protocols, and 
its integrity was verified by field inversion gel electrophoresis (FIGE) with preset 
program number 6 (switch time ramp 0.4–1.5 s, linear shape, forward voltage 
180, reverse voltage 120) of the FIGE MAPPER power supply (BIORAD, Inc.). 
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To generate the small insert DNA library, genomic DNA was randomly sheared 
by sonication. DNA fragments having a size range between 1.5 and 3 kb were 
fractionated on agarose. The ends of the DNA fragments were repaired by using 
T4 DNA polymerase (Roche) as described by the supplier. The repaired DNA 
fragments were subcloned into a derivative of pBluescript SK+vector 
(STRATAGENE). Plasmid DNA carrying the Streptomyces refuineus genomic 
DNA fragments was extracted by the alkaline lysis method, and the insert size of 
1.5 to 3 kb was confirmed by electrophoresis on agarose gels. Using this 
procedure, a library of small-size random genomic DNA fragments representative 
of the entire genome of Streptomyces refuineus was generated. The small insert 
DNA library was analyzed by sequence determination of the cloned genomic 
DNA inserts to generate genomic sequence tags, GSTs. GST sequencing was 
performed by using a 3700 ABI capillary electrophoresis DNA sequencer 
(Applied Biosystems). The average length of the DNA sequence reads was ~700 
bp. Further analysis of the obtained GSTs was performed by sequence homology 
comparison to various protein-sequence databases. The DNA sequences of the 
obtained GSTs were translated into amino acid sequences and compared to the 
National Center for Biotechnology Information (NCBI) nonredundant protein 
database by using known algorithms. A total of 486 Streptomyces refuineus 
GSTs were generated and analyzed by sequence comparison with BLAST. 
Sequence alignments displaying an E value of at least e-5 were considered as 
significantly homologous and retained for further evaluation. One GST clone 
identified by BLAST analysis as encoding a fragment of a nonribosomal peptide 
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synthetase (NRPS) enzyme was selected for the generation of an oligonucleotide 
probe, which was then used to identify the gene cluster harboring this specific 
NRPS gene(s) in the large insert cosmid library. 
Cosmid Library Construction and Screening 
A cosmid library was constructed from the Streptomyces refuineus high 
molecular weight genomic DNA by using a SuperCos-1-derived cosmid vector 
(STRATAGENE). The cosmid arms were prepared as specified by the 
manufacturer. The cosmid library consisted of 864 isolated cosmid clones in E. 
coli DH10B (Invitrogen). These clones were picked and inoculated into nine 96-
well microtiter plates containing LB broth, which were grown overnight and then 
adjusted to contain a final concentration of 25% glycerol. These microtiter plates 
were stored at -80°C and served as glycerol stocks of the cosmid library. 
Duplicate microtiter plates were arrayed onto nylon membranes and crosslinked 
onto the membranes by UV irradiation by using a GS GENE LINKER UV 
Chamber (BIORAD, Inc). Considering an average size of 8 Mb for an 
actinomycete genome and an average size of 35 kb of genomic insert in the 
cosmid library, this library represents roughly a 4-fold coverage of the 
microorganism’s genome. A GST clone identified by BLAST analysis as 
encoding a fragment of a nonribosomal peptide synthetase (NRPS) enzyme was 
selected for the generation of an oligonucleotide probe, which was then used to 
identify the gene cluster harboring this specific NRPS gene(s) in the cosmid 
library. Hybridization oligonucleotide probes were radiolabeled with P32 by using 
T4 polynucleotide kinase (New England Biolabs, Inc.) in 15 ml reactions 
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containing 5 pM of oligonucleotide and 6.6 pM of g-P32 ATP in the kinase 
reaction buffer supplied by the manufacturer. Positive clones were identified, 
cosmid DNA was extracted from 30 ml cultures by the alkaline lysis method, and 
the inserts were entirely sequenced by a shotgun sequencing approach. Two 
overlapping cosmid clones that were detected by the oligonucleotide probe 
derived from the original NRPS GST clone were completely sequenced to 
provide approximately 60 Kb of information. 
Retrofitting Cosmids with Origin of Transfer  
To enable gene deletion, cosmids 024CO and O24CA were retrofitted with 
oriT by replacing kanamycin resistance gene (neo) with oriT and streptomycin 
resistance-gene (aad(A)) cassette from plasmid pIJ778 with primers Neo-OS 
(pIJ778 homologous sequence underlined) and then replacing aad(A) with neo 
with primers OS-Neo (neo homologous sequence underlined) through “Red/ET 
cloning system” (primers in table 2-03). Cosmids 024CO and O24CA containing 
the oriT insertion are designated 024OCO and 024OCA, respectively, and used 
for the disruption of orfS10, orf12, orf19, and NRPS (orf21/orf22). 
 
Table 2-03. Primers for retrofitting cosmids with origin of transfer (pIJ778 
homologous sequence underlined).  
Target ORF Primer 
Neo-OS 5’ TCAAGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCGCGGCATCTTATTTGCCGAC 3’ 
5’ GCGTCG CTTGGTCGGTCATTTCGAACCCCAGAGTCCCGCGTTCCCGCCAGCCTCGCAG 3’ 
OS-neo 5’ TATGCAGAGGCCGAGGC 3’ 
5’ TATATCGTGCGAAAAAGGATGGATATACCGAAAAAATCGCCAGAGTCCCGCTCAGAAG 3’ 
 
Targeted Replacement of orf12, orf19, and NRPS (orf21/orf22) 
Apramycin resistance gene (aac(3)IV) was amplified from plasmid pIJ773 
with forward and reverse primers with flanking regions appropriate for gene 
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replacement. The resulting PCR products were transformed into E. coli 
BW25113/pIJ790 containing cosmid 024OCO or 024OCA. Orf12, orf19 and 
NRPS (orf21/orf22) were separately replaced by aac(3)IV. The resulting cosmids 
pBOB3001, pBOB3002, pBOB3003, and pBOB3004 were transformed into E. 
coli ET12567/pUZ8002 and then introduced into wild-type S. refuineus strain by 
intergeneric conjugation. The double-crossover homologous recombination 
mutant strains were selected for an apramycin-resistant and kanamycin-sensitive 
phenotype. Orf12, orf19, and NRPS (orf21/orf22) mutants were tested by PCR 
amplification with the primers internal to apramycin-resistance marker aac(3)IV 
and to regions external to the replaced genes. The corresponding mutants are 
designated BOB3001, BOB3002, BOB3003, and BOB3004, separately. 
Targeted Replacement of orfS10 
Apramycin resistance gene (aac(3)IV) was amplified from plasmid pIJ773 
with forward and reverse primers with flanking regions appropriate for gene 
replacement. The resulting PCR products were transformed into E. coli 
BW25113/pIJ790 containing cosmid 024OCO. OrfS10 was replaced by aac(3)IV 
and the resulting cosmids pBOB3001 were transformed into E. coli 
ET12567/pUZ8002 and then introduced into wild-type S. refuineus strain by 
intergeneric conjugation. The double-crossover homologous recombination 
mutant strains were selected for an apramycin-resistant and kanamycin-sensitive 
phenotype. OrfS10 mutant were tested by PCR amplification with the primers 
internal to apramycin-resistance marker aac(3)IV and to regions external to the 
replaced genes. The corresponding mutants are designated BOB3001. 
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Targeted Replacement of orf1, orf23, orf24 and orfAS11 
The cassette comprising the apramycin-resistance gene (aac(3)IV) and 
oriT was amplified from plasmid pIJ773 with appropriate forward primers and 
reverse primers. The resulting PCR products were transformed into E. coli 
BW25113/pIJ790 containing cosmid 024CO (024CA). Orf1 and orfAS11 were 
replaced separately by aac(3)IV and oriT cassette and the resulting cosmids 
pBOB3005, pBOB3006 were transformed into E. coli ET12567/pUZ8002 and 
then introduced into wild-type S. refuineus strain by intergeneric conjugation. The 
double-crossover homologous recombination mutant strains were selected for by 
using apramycin-resistant and kanamycin-sensitive phenotypes. Orf1, orf23, 
orf24 and orfAS11 mutants were tested by PCR amplification with the primers 
internal to apramycin resistance marker aac(3)IV and to regions external to the 
replaced genes. The corresponding mutants were designated BOB3005 and 
BOB3006, separately. Primers for gene disruptions in anthramycin biosynthetic 
gene cluster were listed in table 2-04. Primers to test anthramycin mutant strains 
were listed in table 2-05. 
 
Table 02-04. Primers used in gene replacement experiments for anthramycin 
biosynthetic gene cluster from Streptomyces. refuineus. 
Target ORF Primer 
AS10 DAS10-F: 5’ GGCGCCCGAGCCCGCGTCGGCGGCCTGGCCCCGGGCCGGGGGAATAGGAACTTATGAGC 3’ 
DAS10-R: 5’ CCGCCCATCGAGCCGGTCGTCCCGCGGCAACGGCGCGGCCGCTGACGCCGTTGGATAC 3’ 
1 D1-F: 5’ TGCCGCTGCGGCCCCGAGGAGGGCGGGCGCACCCGTCTCAGGAATAGGAACTTATGAGC 3’ 
D1-R: 5’ AAAACCGTGTGGACGTCAATCGCCCCCTGACCTCCGGCAGAAGTTCCCGCCAGCCTC 3’ 
12 D12-F: 5’ GCCGACCATTGAGGCCGATTGCTTCCACTCCGCGGAGACATCTAGAGGAATAGGAACTTATGAGC 3’ 
D12-R: 5’ CCCCCGCCCGGTGCGGCGGCATGTCCTCGGCCGTTGCTCAACTAGTGCTGACGCCGTTGGATAC 3’ 
19 D19-F: 5’ ACGGGCCGGCGTGGGAGGCCACCGGCCTGCCGGGAGGCACTCTAGAGGAATAGGAACTTATGAGC 3’ 
D19-R: 5’ GGTGCTCGGCGAGTACTCGCGGTCCAGCCGGCCTGGCTCAACTAGTGCTGACGCCGTTGGATAC 3’ 
21/22 DNRPS-F: 5’ CCGAGCCCACACGAGAAGGGACGGTGACATCCGCGCGATGTCTAGAGGAATAGGAACTTCATGAGC 3’ 
DNRPS-R: 5’ GTCCGGCGCCGATGACCACCACCGAGCGCCTGTGCAGCTCAACTAGTGCTGACGCCGTTGGATAC 3’ 
23 D23-F: 5’ GATCCACTACGGACGCGCGTGCGTCGACGTGGACACCGGGGAATAGGAACTTATGAGC 3’ 
D23-R: 5’ GACCCCGGCCATCCGGCCGAAGACGTCGGGGAACTCCGTAAGTTCCCGCCAGCCTC 3’ 
24 D24-F: 5’ GCATCGCGGACCGTGCGGACCGCCGTGTCCGTGGACAGCAGGAATAGGAACTTATGAGC 3’ 
D24-R: 5’ GAATCCGCCTCGGCCATGGCGTGGGCCCGCTACGAGTCGGAAGTTCCCGCCAGCCTC 3’ 
S11 DAS11-F: 5’ GCCCGCTCCCGGACGAGGTCGAGCCGGCCCCGCCGTGCCGCGGAATAGGAACTTATGAGC 3’ 
DAS11-R: 5’ CCACAAATCCGCAGCAGCCCAACCGTGCCGATCCTGGTTCAAGTTCCCGCCAGCCTC 3’ 
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Table 02-05. Primers pairs for confirmation of gene deletion in anthramycin 
biosynthetic gene cluster from Streptomyces. refuineus.  
Target ORF Primer 
AS10 TDAS10-F: 5’ CTGCCACGACGAACACGCTG 3’, Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TDAS10-R: 5’ GTGACCCTCGACTGGTG 3’, Am-R: 5’ GTAACCCCAAGGTTGAG 3’ 
1 TD1-F: 5’ CTCGATGGGCGGTCGGGTGG 3’ , Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TD1-R: 5’ TGGACCCGGAGCCTGAG 3’, Am-R: 5’ GTAACCCCAAGGTTGAG 3’. 
12 TD12-F: 5’ CTGTTTTCATGCCGCTTTCC 3’, Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TD12-R: 5’ ACGCAGGCGGTCAGCAC 3’, Am-R: 5’ GTAACCCCAAGGTTGAG 3’. 
19 TD19-F: 5’ GGTCGCCTACCAGTTCTCC 3’ , Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TD19-R: 5’ GTTGCGTGCCGCGAAG 3’, Am-R: 5’ GTAACCCCAAGGTTGAG 3’ 
21/22 TDNRPS-F: 5’TACCTGCGCCAGCACGAG 3’ , Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TDNRPS-R: 5’ ACAGCAGGTGATGGGTGTC 3’, Am-R: 5’ GT AACCCCAAGGTTGAG 3’ 
23 TD23-F: 5’ CTTCGAACGGGAGCCG 3’ , Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TD23-R: 5’ GCGGCACAGCGAGTCC3’, Am-R: 5’ GTAACCCCAAGGTTGAG 3’ 
24 TD24-F: 5’ AGGATGTACGCGCCCG 3’ , Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TD24-R: 5’CTATCTGAAGGAGATGGG 3’, Am-R: 5’ GTAACCCCAAGGTTGAG 3’ 
S11 TDAS11-F: 5’ AGGCACGGGATTTCCCGGAC 3’, Am-F: 5’ CGAGAATGACCACTGCTG 3’ 
TDAS11-R: 5’ CCCGCAAGAGACAGGC 3’, Am-R: 5’ GTAACCCCAAGGTTGAG 3’ 
 
Preparation of Possible Biosynthetic Intermediates of Anthramycin 
L-kynurenine, 3-hydroxy-L-kynurenine, hydroxyanthranilic acid were 
purchased directly from Sigma Corporation. 4-methyl-3-hydroxyanthranillic acid 
was prepared by catalytic hydrogenation of 4-methyl-3-hydroxy-2-nitrobenzoic 
acid (Aldrich, Inc.) with Pd/C and H2 at 1atm in ethanol.  
Chemical complementation of anthramycin 
For chemical complementation, corresponding compounds were added 
directly to the production medium to a final concentration of 2 mM beginning of 
fermentation.  
Production and Detection of Anthramycin 
S. refuineus and its mutant derivatives were cultured in 50 ml seed 
medium at 47°C for 24 hr. A 5% inoculum was then added to 50 ml production 
medium and cultured at 47°C  for 24 hr. Anthramycin was extracted from the 
production medium with 50 ml butanol. Butanol extracts were concentrated in 
vaccuo and redissolved in MeOH. Antibacterial activity of anthramycin was 
detected by thin-layer chromatography bioautography. Anthramycin butaol 
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extracts (dissolved in MeOH) were run on 25DC-Alufolien Kieselgel plates with 
solvent MeOH:CHCl3 (1:9); LB agar containing indicator strain Bacillus sp. TA 
was overlaid on TLC plates and cultured at 37°C for 20 hr to detect anti-Bacillus 
activity (evidenced by growth inhibition zones) of anthramycin. Anthramycin 
production was further confirmed by HPLC/MS. Mass spectrometry was 
performed by using ThermoFinnigan (San Jose, CA) TSQ Quantum triple 
quadrupole mass spectrometer equipped with a standard electrospray ionization 
source outfitted with a 100 mm I.D. deactivated fused Si capillary. The injection 
volume was 10 ml. Anthramycin was separated from cometabolites by using a 
Jupiter minibore 5 mm C18 column (2.0 mm x 15 cm) with a linear 
wateracetonitrile gradient (ranging from 95:5 to 5:95 H2O:CH3CN) containing 10 
mM ammonium acetate. The flow rate was 0.2 ml/min. The mass spectrometer 
was operated in the positive (or negative) ion mode, and the electrospray needle 
was maintained at 4,200 V. The ion transfer tube was operated at 35 V and 
342°C (~35 V and 300°C for negative). The tube lens voltage was set to 85 V 
(~220 V for negative). Source CID (offset voltage between skimmer and the first 
ion guide, Q00) was used at 15 V. The mass spectrometer was operated in full 
scan mode with Quad 1. The mass spectral resolution was set to a peak width of 
0.70 u (full width at half maximum, FWHM). Full scan spectra were acquired from 
m/z 150.0 to 700.0 (m/z 150.0 to 1200.0 for negative) over 1.0 s. Data were 
acquired in profile mode. The electron multiplier gain was set to 3 x 105. 
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CHAPTER III 
 
REASSEMBLY AND HETEROLOGOUS EXPRESSION OF ANTHRAMYCIN 
BIOSYNTHETIC GENE CLUSTER 
 
Introduction 
Numerous drugs that have been used clinically are derived from natural 
products produced by bacterial, fungi or botanical sources.1-4 Generally 
biosynthetic genes of natural products with potent biological activities are 
clustered together on their host genome. Over the past three decades, a large 
amount of gene clusters have already been identified as being responsible for 
the biosynthesis of natural products that have been demonstrated to play 
important roles for the survival and growth of their producers.5-10 Those natural 
products can be developed into a variety of active compounds, some of which 
have been employed in clinical settings.   
Cloning of natural product gene clusters has made the study of the 
biosynthesis of natural products relatively easier, because researchers are able 
to deduce biosynthetic pathways based on their chemical structures together with 
corresponding biosynthetic gene clusters. The biosynthetic knowledge for natural 
products has enabled subsequent modifications and rearrangements of these 
natural products biosynthetic gene clusters, called combinatorial biosynthesis, 
aimed at generating novel “natural products”.11-13  
In order to confirm the function of cloned biosynthetic gene clusters from 
the genome of their producing organisms and investigate the biosynthetic 
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pathways of natural products, genetic manipulation systems for the producers of 
target natural products have to be established first. Afterwards, gene disruptions 
are normally utilized to demonstrate whether a gene cluster is related to the 
biosynthesis of a certain natural product.14, 15 One question for the study of 
natural product biosynthesis is that the genetic systems for all microorganisms 
can not be treated in a similar fashion and it is not easy to establish mature 
genetic manipulation systems for all microorganisms. Even for the well-studied 
Streptomyces, which can produce more that 70% of known antibiotics, to date 
there are only a few transformation methods that can be employed and not all 
Streptomyces strains are capable of being genetically manipulated as 
expected.16 In terms of fungi, which have been proven to produce a great number 
of secondary metabolites with novel structures and potent biological activities, 
the genetic systems are notoriously difficult to handle17, 18 and the research work 
dependent on the genetic manipulation for fungi derived natural products is more 
risky. Additionally, most slow growing fungi and bacteria are susceptible to 
contamination from other fast growing bacteria like E. coli, bringing another 
technical obstacle for the biosynthetic study on the direct producers of natural 
products.  
An alternative and increasingly applied approach for natural product 
biosynthetic studies is to heterologously express natural product biosynthetic 
gene clusters. In this method, the targeted natural product gene cluster is cloned 
into a suitable vector and subsequently transformed into other genetically-related 
hosts which can be easily manipulated. The function of a given biosynthetic gene 
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cluster can be validated if the target natural product can be detected in the 
modified heterologous host. In the past decade, heterologous expression has 
become a very useful method for the biosynthetic study of natural products, 
especially those produced by microorganisms without suitable genetic 
manipulation systems.19, 20 The natural products from culturable microorganisms 
account for only approximately 1% of all the natural products in nature. The 
majority of natural products are produced by those unculturable organisms that 
are difficult to culture using present known culture conditions.21, 22 What we can 
do so far is simply to isolate genomic DNA from environmental samples and 
identify biosynthetic gene clusters for natural products from inside. For those 
natural product biosynthetic gene clusters from unculturable organisms or 
microorganisms that can not be genetically manipulated, heterologous 
expression of gene clusters is probably the best, or perhaps the only, choice for 
further genetic and biochemical studies.  
Typically, after the isolation of a microorganism, genomic DNA is cloned 
into a vector such as a cosmid, fosmid or bacterial artificial chromosomes (BACs) 
with DNA fragments of a certain size in the vectors.23-26 If the DNA fragment in a 
single vector can harbor a complete natural product biosynthetic gene cluster, the 
vector containing this DNA fragment can be transformed into another host for 
heterologous expression. In most cases, however, the biosynthetic gene clusters 
for natural products are very large with the size of some gene clusters up to 200 
kb and can not be maintained in a single vector.27, 28 To solve this problem, some 
laboratories utilized recombinant genetic methods to tether different portions of a 
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natural product biosynthetic gene cluster and then clone this complete gene 
cluster into a single vector for heterologous expression.29 This method has been 
proven to be viable, but the size and complexity of a biosynthetic gene cluster 
makes it very difficult to find suitable restriction sites for reconstructing the 
complete biosynthetic gene clusters from partial gene clusters using traditional 
digestion/ligation methods. This approach is relatively impractical because of the 
difficulty in genetically manipulating long natural product biosynthetic gene 
clusters due to the difficulty in identifying unique restriction sites in natural 
product biosynthetic gene clusters.  
To circumvent these problems, a new method called “Red/ET cloning 
system”30 has recently been developed for the recombination of homologous 
sequences in E. coli, which is probably the easiest host for DNA manipulation. 
The basic principle of this recombination system is based on the presence of 
several proteins that can facilitate DNA homologous recombination in the same E. 
coli cells31-33 as have been described in chapter two. Originally this 
recombination method was designed and utilized for the targeted replacement of 
biosynthetic genes in the genome of E. coli and later for manipulation of 
biosynthetic gene clusters in Streptomyces.24, 34, 35 This method has been 
demonstrated to be very useful and successful, especially for the genetic work 
related to Streptomyces. The broad applicability of this new approach has 
revolutionized the traditional gene replacement methods in prokaryotic cells. 
 In the past several years, several new methods derived from the “Red/ET 
cloning system” were developed for the recombination of partial biosynthetic 
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gene clusters from separate vectors into complete natural product gene clusters 
and have been demonstrated to be more convenient compared with previous 
genetic methods. Recombination systems derived from “Red/ET cloning system” 
for the functional reconstruction of large natural product biosynthetic gene 
clusters from fragments on separate vectors were first applied for the 
reconstruction of gene clusters for myxobacterial metabolites. Myxobacteria are 
capable of producing a great variety of natural products with novel structures and 
activities and have aroused the interests of researchers from all over the world.36-
38 However, the biosynthetic study of natural products from myxobacteria has 
encountered difficulties. For example it is not easy to isolate and purify a single 
myxobactrial strain from the environment, the growth of myxobacteria is relatively 
slow and can be easily contaminated and the genetic systems for myxobacteria 
have not been well established, etc.39, 40 Rolf Muller’s research group has done a 
lot of work for the improvement of methods to heterologously express the 
biosynthetic gene clusters they have identified from myxobacteria, which will 
greatly facilitate further genetic and biochemical work.  
In 2005, Dr. Muller’s group developed the first recombination based 
approach through which they were able to recombine a 3.5 kb DNA fragment 
containing a minority of the myxochromide S gene cluster together with the 
zeocin-resistance gene into another vector with the majority of the myxochromide 
S gene cluster using “Red/ET cloning system”.41  The complete myxochromide S 
biosynthetic gene cluster, which was identified from the genome of Stigmatella 
aurantiaca, was reconstructed from two partial gene clusters and successfully 
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expressed in a heterologous host Pseudomonas putida (figure 3-01).  
 
 
Figure 3-01. Genetic method to recombine myxochromide S biosynthetic gene 
cluster from Stigmatella aurantiaca on the base of “Red/ET cloning system” 
(copyright of Dr. Rolf Muller research group). 
 
Subsequently, Muller’s group developed another method through which 
they first inserted two different cassettes into two partial myxothiazol gene 
clusters via “Red/ET cloning system” and then reconstituted them into a complete 
gene cluster from two cosmids through traditional ligation (figure 3-02).42 
Although the myxothiazol originally produced by Stigmatella aurantiaca could be 
heterologously expressed after its biosynthetic gene cluster was transferred into 
Myxococcus xanthus, one dramatic drawback for this reconstitution method was 
the requirement to insert additional DNA sequence, at least one restriction 
enzyme site with 6 bp, into myxothiazol biosynthetic gene cluster, which might 
effect the function of the complete gene cluster and the production of a natural 
product.  
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Figure 3-02. Genetic method to recombine myxothiazol biosynthetic gene cluster 
from Stigmatella aurantiaca on the base of “Red/ET cloning system” (copyright of 
Dr. Rolf Muller research group).  
 
The research work for heterologous expression of natural product 
biosynthetic gene clusters from myxobacteria through recombination technology 
derived from “Red/ET cloning system” has demonstrated the feasibility of using 
this novel technique to reconstruct and reassemble natural product biosynthetic 
gene clusters from different sources. However, despite the successful expression 
of natural product biosynthetic gene clusters as described above, those two 
reconstruction approaches, which are based on the principle of “Red/ET cloning 
system” seem not to be the final “answer” and still need further optimization or 
renovation because of some limitations  associated with them.  
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Results and Discussions 
In our laboratory, we have successfully applied “Red/ET cloning system” in 
Streptomyces refuineus, the producer of antitumor natural product anthramycin.43 
The function and boundaries of anthramycin biosynthetic gene cluster have been 
demonstrated using this new gene mutation approach. A more direct method, 
heterologous expression, can also be utilized to further confirm the function of 
this anthramycin gene cluster. The anthramycin biosynthetic gene cluster can be 
cloned into a suitable vector and the recombinant vector harboring the complete 
anthramycin gene cluster will be transformed into other genetic related hosts for 
heterologous expression.  
The size of the anthramycin biosynthetic gene cluster is relative large 
(more than 30 kb) and we had two cosmids on hand, each harboring partial 
anthramycin gene cluster with a roughly 10 kb DNA overlap region. In order to 
recombine these two partial anthramycin clusters into the same vector, we 
developed a new recombination method, which was based on the “Red/ET 
cloning system” and took advantage of the 10 kb overlap region as a 
homologous sequence for the recombination of larger DNA fragments.  
The basic principle of the gene replacement method, “Red/ET cloning 
system”, is that recombination will occur between homologous sequences in E. 
coli BW25113/pIJ790 which can express certain proteins to facilitate 
recombination between DNA homologous sequences. Since there is an 
approximate 10 kb overlap region between these two partial anthramycin 
biosynthetic gene clusters, we expected that this homologous region could be 
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used as a homologous sequence on one side. The remaining problem was to 
identify and add additional homologous DNA sequences on the other side in 
order to reassemble two anthramycin partial gene clusters.  
Serendipitously, we noticed that in plasmids pIJ773 and pIJ778 that were 
commonly used in “Red/ET cloning system”30, there was a homologous 
sequence region of 341 bp between the origin of transfer (oriT) and apramycin 
resistance gene (aac(3)IV)/streptomycin resistance gene (aadA). We speculated 
that the reason might be that the coding region of aac(3)IV in pIJ773 was 
replaced by aadA to yield pIJ778 using the “Red/ET cloning system” and the 
promoter region of aac(3)IV was still left on the plasmid. This homologous 
promoter region could be exploited to generate recombinogenic cassttes for the 
recombination of partial gene clusters by inserting this homologous region into 
certain locations into the vectors. Thus, we could amplify the apramycin 
resistance gene (aac(3)IV) from pIJ773 and the streptomycin resistance gene 
(aadA) from pIJ778, with the promoter region as the homologous sequence on 
the same side. The XbaI restriction site was added outside the homologous 
region with 39 bp flanking sequences on both sides of the PCR products for 
PCR-targeting replacement. Other restriction sites that could not be identified 
from the gene cluster could also be utilized and placed before the homologous 
region. Flanking sequences were selected from the anthramycin biosynthetic 
gene cluster for homologous recombination to insert aac(3)IV and aadA into 
those corresponding target regions. The aac(3)IV gene was utilized to replace  a 
240 bp fragment inside orf7 of the anthramycin gene cluster in cosmid 024CA to 
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yield cosmid FCA and aadA was used to replace a 200 bp fragment located 4425 
bp upstream of orf1 of the anthramycin gene cluster to yield cosmid FCO. 
The linear PCR products of aac(3)IV and aadA with homologous 
sequence on the upstream side were transformed into E. coli BW25113/pIJ790 
strains containing cosmids 024CA and 024CO, respectively. In the 10 kb 
overlapped region between the two anthramycin partial gene clusters, DraI was 
recognized as a single-cut restriction enzyme site for anthramycin biosynthetic 
gene cluster. After inserting the aadA cassette into cosmid CO to produce cosmid 
FCO, FCO was cut with XbaI and DraI to yield a 15.9 kb DNA fragment with DNA 
sequences homologous to cosmid FCA on both sides of this DNA fragment. The 
15.9 kb DNA fragment was purified after enzymatic digestion and transformed 
into E. coli BW25113/pIJ790 containing cosmid FCA. Recombination occurred on 
both sides at the promoter homologous sequence and the overlapped DNA 
region in the anthramycin gene cluster. Cosmid CAO, containing the complete 
anthramycin biosynthetic gene cluster, was selected by isolating streptomycin 
resistant and apramycin sensitive colonies because aac(3)IV in cosmid FCA was 
replaced by aadA from the linear 15.9 kb DNA fragment. PCR was used to verify 
the correct orientation of the inserted sequence and sequencing analysis proved 
the correctness of the recombinant cosmid.  
To integrate cosmid CAO into the genome of other Strepomyces hosts, an 
attachment site of phage c31 (attP) was inserted into the vector. After 
transformation of the recombinant vector with attp site into Streptomyces, vector 
harboring the biosynthetic gene cluster could be integrated into attB site on the 
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genome with high efficiency. An integrase gene (int), attachment site of phage 
c31 (attP) together with the tetracycline-resistance gene were cut from plasmid 
pIJ78744 as a DNA fragment by a DraI/BsaI digestion and utilized to replace the 
ampicillin-resistance gene (bla) in cosmid CAO to yield comid CAO-2. To facilitate 
efficient transformation between E. coli and Streptomyces strains, an oriT was 
inserted into CAO-2 to yield cosmid CAO-3 by replacing the kanamycin 
resistance gene (neo) with a cassttee containing the apramycin resistance gene 
(aac(3)IV) and oriT that was cloned from plasmid pIJ773. Cosmid CAO-3 was 
transformed into E. coli ET12567/pUZ8002 and subsequently transformed into S. 
lividans TK24 and S. coelicolor M595 through intergeneric conjugation. 
Integration of cosmid CAO-3 was confirmed by the apramycin resistance 
phenotype and PCR amplification of DNA sequences from both the anthramycin 
biosynthetic gene cluster and the vector. The detailed strategy for the reassembly 
and heterologous expression of anthramycin biosynthetic gene cluster was 
elucidated in figure 3-03.  
 
 
127 
 
Figure 3-03. Complete cloning strategy for reassembly and heterologous 
expression of anthramycin biosynthetic gene cluster.  
 
The fermentation broth of S. lividans TK24/CAO-3 and S. coelicolor 
M595/CAO-3 was subjected to the detection of anthramycin by using TLC 
bioautography (anti-Bacillus activity) and HPLC-MS analysis. Anthramycin could 
be heterologous expressed in S. lividans TK24 instead of S. coelicolor. 
Anthramycin could not be heterologously expressed in S. coelicolor probably 
because S. coelicolor was not a suitable host for anthramycin biosynthetic gene 
cluster or the regulation and promoter systems of anthramycin gene cluster were 
not compatible with S. coelicolor. We could detect the formation of anthramycin 
from the fermentation broth of S. lividans TK24/CAO-3. Interestingly, anthramycin 
could not be produced when this producing strain was cultured at 28°C, the 
normal temperature for the culture of S. lividans. When we changed the cultural 
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temperature to 37°C, 47°C and 52°C, anthramycin production was only detected 
at 47°C but not 37°C and 52°C, suggesting a temperature dependent expression 
mechanism of the anthramycin biosynthetic gene cluster (figure 3-04). It has also 
been observed that the stability of anthramycin in S. lividans TK24 was not very 
high. Only in the first two days could anthramycin be detected from the 
fermentation broth and after the third day we failed to observe anthramycin in 
production medium, perhaps because anthramycin has a high toxicity and S. 
lividans has a self-protection mechanism to inactive anthramycin after its 
production.   
 
 
Figure 3-04. HPLC/MS results of the anthramycin biosynthetic gene cluster 
heterologous expression. (Left: anthramycin from S. refuineus. Middle: negative 
control from S. lividans TK24. Right: anthramycin from S. lividans TK24/CAO-3.) 
 
In our laboratory, on the basis of “Red/ET cloning system”, which was 
originally designed to mutate target genes on the genome, we developed a new 
method to recombine partial biosynthetic gene clusters and used anthramycin 
biosynthetic gene cluster as a case study to prove the feasibility of this new 
method. The successful reassembly and heterologous expression of the 
anthramycin biosynthetic gene cluster in S. lividans TK24 demonstrated our 
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method could be utilized to assemble fragmented gene clusters into complete 
biosynthetic gene clusters and could be applied for the heterologous expression 
of many other natural product biosynthetic gene clusters, notebly those from 
unculturable organisms.  
 
Materials and methods 
General DNA Procedures 
DNA manipulation was conducted according to standard methods. Cosmid 
DNA was isolated and purified from E. coli strains by using plasmid miniprep and 
gel extraction kits (Qiagen). All transformations in E. coli were performed by 
electroporation by using a GenePulser electroporator (Biorad) with a 100 V, 30 
ms pulse. Genomic DNA from Streptomyces strains was isolated by using the 
WizardTM genomic DNA purification kit (Promega). Primers were synthesized by 
Operon Biotechnologies (Huntsville, AL, USA). Intergeneric conjugation was 
performed according to Kieser et al. with modifications as described below.  
Bacterial strains and media 
Targeted gene replacement experiments were performed in E. coli strain 
BW25113 that contained the plasmid pIJ790. E. coli ET12567 that contained the 
RP4 derivative pUZ8002 was used for intergeneric conjugation between E. coli 
and Streptomyces. The heterologous expression host was Streptomyces lividans 
strain TK24 and Streptomyces coelicolor M595. Bacillus sp. TA (NRRL B-3167) 
was used as an indicator strain to test the activity of anthramycin. E. coli strains 
were maintained in LB medium that contained the appropriate antibiotics for 
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selection. S. refuineus was grown in SRS medium (0.5% N-Z Amine B, 0.2% 
yeast extract, 0.2% soytone, 1.0% potato starch, 0.5% mannitol, 0.015% FeSO4, 
2% agar, pH 7.0) and anthramycin production was performed in production 
medium AP1 (1% corn starch, 2% peptonized milk, 0.3% yeast extract, pH 7.0). 
AS1 medium (0.1% yeast extract, 0.02% L-alanine, 0.02% L-arginine, 0.05% L-
asparagine, 0.5% starch, 0.25% NaCl, 1% Na2SO4, 2% agar) and MS medium (2% 
mannitol, 2% soya, 2% flour agar) were used for conjugation. 
Retrofitting donor cosmids with recombination cassettes 
The apramycin-resistance gene (aac(3)IV) cassette was amplified by PCR 
from plasmid pIJ773 by using primers UPaacF/UPaacR (table 3-01) and 
transformed into E. coli BW25113/pIJ790/CA. Transformants were selected for 
resistance to apramycin at 30 μg/mL. The resulting cosmid FCA, in which a 240 
bp DNA fragment in the anthramycin biosynthetic gene ORF7 was exchanged 
with PCR-targeted recombination, was purified by gel electrophoresis. A 200 bp 
DNA fragment that was 4425 bp upstream of the anthramycin biosynthetic cluster 
on cosmid CO was exchanged in a similar fashion. In this case, the streptomycin-
resistance gene (aadA) cassette was amplified from plasmid pIJ778 with primers 
DNaadF/DNaadR (table 3-01) and transformed into E. coli BW25113/pIJ790/CO. 
Transformants that were resistant to streptomycin (30 μg/mL) contained cosmid 
FCO, which was subsequently purified by gel electrophoresis. The insertion of 
recombinogenic cassettes was verified by PCR using primers TFCA-1/ UPaacR 
and TFCO-1/ DNaadR (table 3-01). 
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Table 3-01. PCR-targeting primers to reassemble anthramycin biosynthetic gene 
cluster (Restriction sites are in bold; the homologous targeting sequence is 
underlined). 
primer sequence 
UPaccF 5’-ACCGAGCCGATCGGGTAGAGCACCGCACCGTAGCGGTCGCTCTAGAGCTGACGCCGTTGGATAC-3’ 
UPaccR 5’-CCCTGGTACGACGTGTGGCTCCCCGGGTCCGCCGTGGAGGACTAGTGGAATAGGAACTTATGAGC-3’ 
DNaddF 5’-CACGTGCGGCCGCACGAGGGCGAGTCGGCCGCCGCGGAGGTCTAGAGCTGACGCCGTTGGATAC-3’ 
DNaddR 5’-GCGCCACCGTCACGCTCTCCACCCGCAGCCCCGGCACCATACTAGTGCGGCATCTTATTTGCCGAC-3’ 
ATF 5’-TCAAGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCGGAATAGGAACTTATGAGC-3’ 
ATR 5’-GCGTCGCTTGGTCGGTCATTTCGAACCCCAGAGTCCCGCAAGTTCCCGCCAGCCTC-3’ 
TFCO-F1 5’-CTGCGCCACTTCCTCGAC 3’ 
TFCA-F1 5’ AAGTGGGGTTCCACTACC 3’ 
TF 5’-GTAACCCCAAGGTTGAG-3’ 
TR 5’-TGTCCAATTATGTCACACCAC-3’ 
TD-1 5’ -CTCGATGGGCGGTCGGGTGG- 3’ 
T1-R2 5’-TGGACCCGGAGCCTGAG- 3’ 
TD-10 5’-CTGCCACGACGAACACGCTG-3’ 
T10-R2 5’-GTGACCCTCGACTGGTG-3’ 
TD-11 5’-AGGCACGGGATTTCCCGGAC-3’ 
TS11-R2 5’-CCCGCAAGAGACAGGC-3’ 
 
Reconstruction of the complete anthramycin pathway 
Cosmid FCO was restricted with XbaI/DraI and the resulting gel-purified 
15.9 kb fragment was transformed into E. coli BW25113/pIJ790/024FCA by 
electroporation. Transformants that contained the resulting cosmid CAO, which 
contained a 15.9 kb fragment that was exchanged into cosmid FCA were 
selected by resistance to streptomycin (30 μg/mL). Cosmid CAO was purified by 
gel electrophoresis and confirmed by PCR with primers TFCA-F1/ DNaddR (table 
3-01). 
Retrofitting fusion cosmid with integrase and origin of transfer 
Insertion of origin of transfer (oriT) and integrase (int) genes into the 
reconstructed cosmid was performed according to established protocols with 
minor modifications. Plasmid pIJ787 was digested with DraI and BsaI, and the 
resulting 5 kb DNA fragment, which contained the integrase cassette flanked by 
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approximately 100 bp of bla sequence upstream and 300 bp of bla sequence 
downstream of the integrase cassette, was gel purified and transformed into E. 
coli BW25113/pIJ790/CAO. Selection for tetracycline resistant (5 μg/mL) clones 
resulted in strains that contained cosmid CAO-2. The apramycin-resistance/origin 
of transfer gene (aac(3)IV/oriT) cassette was amplified from plasmid pIJ773 with 
primers ATF/ATR (table 3-01). The resulting gel-purified PCR product was 
transformed into E. coli BW25113/pIJ790/CAO-2, so that apramycin resistance 
could replace the kanamycin resistance gene in cosmid CAO-2 with aac(3)IV/oriT. 
The resulting cosmid 024CAO-3 was purified and transformed into E. coli 
ET12567/pUZ8002. 
Heterologous expression of the anthramycin cluster  
Cosmid CAO-3 was transformed into Streptomyces lividans TK24 and 
Streptomyces coelicolor M595 by intergenetic conjugation with E. coli 
ET12567/pUZ8002/024CAO-3. Transconjugants were selected on MS or AS-1 
medium (50 μg/mL apramycin) and exconjugates were verified by amplifying 
isolated genomic DNA with four sets of primers on bracketing ends of the gene 
cluster and in the cosmid sequence (Table 3-01). A Streptomyces lividans TK24 
or Stretomyces coelicolor integrant that harbored cosmid CAO-3 was cultured in 
AP1 seed medium (50 mL) at 47°C for 24 h. A 5% inoculum was then added to 
production medium AP1 (50 mL) and incubated at 47°C for 24 h. Anthramycin 
was extracted from the production medium with butanol (50 mL). Butanol 
fractions were dried over anhydrous MgSO4, concentrated in vacuo, and 
redissolved in MeOH directly prior to analysis. 
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Assays for anthramycin production 
Antibacterial activity of anthramycin was detected by thin-layer 
chromatography bioautography and HPLC–MS. Anthramycin (dissolved in MeOH) 
was chromatographed on 25DC-Alufolien kieselgel plates (Merck) that were 
eluted with MeOH/CHCl3 (1:9) and then visualized by bioautography. LB agar 
(~55°C) that was inoculated with indicator strain Bacillus sp. TA was poured on 
TLC plates and cultured at 37°C for 20 h to detect anti-Bacillus activity of 
anthramycin.  Anthramycin production was further confirmed by HPLC–MS 
analysis by using a JupiterTM minibore C-18 column (2.0 mm x 15 cm; 
Phenomenex, Torrance, CA, USA) with a linear water/acetonitrile gradient 
(H2O/CH3CN, 95:5 to 5:95) that contained NH4OAc (10 mm) at 0.2 mL/min flow 
rate. Mass spectrometry was performed by using ThermoFinnigan TSQ Quantum 
triple quadrupole mass spectrometer equipped with a standard electrospray 
ionization source that was outfitted with a deactivated fused Si capillary (100 mm 
i.d.). The injection volume was 10 mL. Mass spectrometery was performed in the 
positive and negative-ion mode, and the electrospray needle was maintained at 
4200 V. The ion transfer tube was operated at 35 V and 342°C (~35 V and 300°C 
for negative). The tube lens voltage was set to 85 V (~220 V for negative). 
Source CID (offset voltage between skimmer and the first ion guide, Q00) was 
used at 15 V. 
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CHAPTER IV 
 
CHARACTERIZATION OF A NOVEL NITROSOSYNTHASE ORF36 FROM 
EVERNINOMYCIN BIOSYNTHETIC GENE CLUSTER IN MICROMONOSPORA 
AFRICANA 
 
Introduction 
Natural products produced by bacteria, fungi and plants are a great source 
of valuable compounds or novel chemical structures that have been 
demonstrated to have potential in industry, especially in drug discovery. A variety 
of natural products have been extracted and purified from their corresponding 
producers and shown to possess potent biological activities that we have used 
medically for thousands of years.1-3 The last 100 years have witnessed many 
scientific developments in natural product biosynthesis and total synthesis of 
these interesting and bioactive compounds. 
Among the natural products that have been discovered so far, an 
intriguing class of natural products contain deoxysugars which have been 
experimentally found to be bonded to core chemical structures that are derived 
from PKS or NRPS.4-6 The functions of these side-chain deoxysugars actually 
play very important roles in their biological activities and should not be 
undervalued.7, 8 The biosynthesis of these deoxysugars has become much 
clearer after the identification of their biosynthetic genes.9-11 Typically these 
dexosugars are derived from the common precursors such as NDP-4-keto-6-
deoxy-ߙ-D-glucose and fructose 6-phosphate, as has been discussed in Chapter 
One. The biosynthesis of deoxysugars requires the involvement of dehydratases, 
 
 
140 
ketoreductases, isomerases, methyltransferases and aminotransferases. These 
deoxysugars are utilized in the biosynthetic pathway in the form of NDP sugars. 
Glycosyltransferases are responsible for the attachment of deoxysugars to the 
core structures in natural products after the formation of the mature 
dexosugars.12  
A great many deoxysugars harbor free amino groups at C3 or C4 
positions.13-15 The amino groups are transferred onto deoxysugars by the 
pyridoxal 5’-phosphate (PLP)/pyridoxamine 5’-phosphate (PMP)-dependent 
transamination reaction catalyzed by aminotransferases.6 Despite the existence 
of large quantities of oxidases in vivo, most of the amine groups in amino sugars 
can not undergo further oxidation and only approximately less than ten 
nitro/nitroso sugars have been identified from deoxysugar-containing natural 
products, including everninomycin, rubradirin, kijanimicin, respinomycins, 
arisostatins and viriplanins.16-23 Both amino sugars and nitro sugars have been 
demonstrated to be very important for the biological activities of their precursor 
natural products, for example, in the interaction between natural products and 
their targets or the signal interaction among their producers.24, 25 However, 
natural products with different amino sugars and nitro sugars have diverse 
biological activities even if the rest of the natural product structure remains 
unchanged. Everninomycin represents a very good example for elucidation of the 
functions and roles of amino sugars and nitro sugars in natural products. The 
everninomycin producer Micromonospora africana can actually produce several 
structurally related natural products, among which are everninomycin with a nitro 
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sugar as the major product, and “compound 5”, which is similar to everninomycin 
except for an amino sugar at position C65 instead of a nitro sugar as shown in 
Figure 4-01.  Despite this minor structural difference, everninomycin and 
“compound 5” exhibit dramatically different biological activities toward a spectrum 
of bacteria. The range of activities in the everninomycin antibiotics indicate that 
the nitro group is critical for the biological activity of nitro group containing natural 
products. Thus the question of how the nitro sugars in natural products are 
biosynthesized has aroused great interest.  
 
 
 
 
 
 
Figure 4-01. Everninomycin and “compound 5” produced by Micromonospora 
africana.  
 
Before our biosynthetic studies of nitro sugars in natural products, the 
formation of several other classes of nitro groups in natural products have been 
well investigated. These previously studied nitro groups containing natural 
products include small aromatic compounds containing nitro groups. The 
biosynthetic mechanisms for the formation of nitro groups can be divided into two 
major groups: direct electrophilic nitration of aromatic groups by NO2+ and 
enzymatic oxidation by N-oxidases. In the first group, NO2+ is produced in vivo 
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and able to attack the aromatic group by an electrophilic reaction to yield an aryl 
nitro functional group. Two representative examples for this class of nitration 
mechanism are thaxtomin produced by the plant pathogen Streptomyces 
turgidiscabies26 and dioxapyrrolomycin produced by Streptomyces fumanus27 as 
previously introduced in Chapter One. In the second group, the nitro groups on 
the aromatic rings are derived from amino groups and certain N-oxidases from 
natural product biosynthetic gene clusters are responsible for the oxidation of 
amino groups to nitro groups. To date, only two examples for the biosynthesis of 
aryl nitro groups catalyzed by N-oxidase have been reported: pyrrolnitrin 
produced by Pseudomonas fluorescens28 and aureothin from Streptomyces 
thioluteus (figure 4-02).29-33 In the biosynthetic gene cluster of pyrrolnitrin, PrnD 
has been demonstrated to be an N-oxidase that can oxidize an aryl amino group 
to an aryl nitro group.34 AurF is another N-oxidase identified in the biosynthetic 
gene cluster of aureothin and capable of catalyzing the oxidation of para-
aminobenzoic acid (pABA) with an amino group to para-nitrobenzoic acid (pNBA) 
with a nitro group.30, 35 Although the above two N-oxidases are able to mediate 
the oxidation of an amino group to a nitro group through the same intermediates: 
a hydroxylamine group and a nitroso group, the mechanisms involved in these 
oxidation reactions are dramatic different: PrnD is an Fe-S cluster N-oxidase 
while AurF is a di-nuclear N-oxidase that requires two metal ions at its active site 
for its N-oxidase activity.  
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Figure 4-02. Flavin-dependent oxidation reactions catalyzed by DszC from 
Rhodococcus erythropolis (a) and IBAH from Streptomyces viridifaciens (b).  
 
 
In the case of nitro sugar biosynthesis, we know through isolation studies 
that natural products harboring amino sugars can also be produced by 
microorganism producers for nitro sugar containing natural products, we 
speculate that those nitro sugars are derived from amino sugars through the 
oxidation reactions catalyzed by N-oxidases. The oxidation of amino sugars to 
nitro sugars very possibly occurs after the deoxy sugar activation by NDP 
because in general the modifications of deoxysugars are carried out at nucleotide 
sugar stage.24 A hydroxylamine group and a nitroso group are proposed to be the 
two possible intermediates for this N-oxidation reaction.  
Here in our laboratory, we used TDP-L-evernitrose in everninomycin as a 
model compound to study the biosynthetic mechanism of nitro groups on sugars. 
We identified a flavin-dependent oxidase ORF36 from the reported 
everninomycin biosynthetic gene cluster based on the comparative genomic 
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analysis of everninomycin biosynthetic gene cluster and the gene cluster of 
avilamycin which is a natural product structurally similar to everninomycin but 
does not harbor a nitro sugar. ORF36 also shows similarity with other flavin-
dependent oxidases. For example, monooxidase DszC from Rhodococcus 
erythropolis has been demonstrated in vitro to oxidize a sulfide to a sulfone36 and 
IBAH which has been shown to oxidize an aliphatic amine group to an aliphatic 
hydroxylamine group during valanimycin biosynthesis.37-39 The characterizations 
of these flavin-dependent oxidases further support our prediction for the function 
of oxidase ORF36 from the evernionmycin gene cluster in nitro sugar 
biosynthesis. 
 We cloned gene orf36 from the genomic DNA of everninomycin producer 
M. africana and expressed ORF36 in E. coli BL21(DE3) to obtain soluble protein 
ORF36. The function of ORF36 was demonstrated in vitro to be a flavin-
dependent nitrososynthase responsible for the oxidation of an amino sugar to a 
nitroso sugar with a hydroxylamine sugar as an intermediate.  
 
Results and Discussion 
Identification of a nitrososynthase from Everninomycin biosynthetic gene cluster 
 Everninomycin is an oligosaccharide natural product that is composed of 
two dichloroisoeverninic acid moieties that are derived from an iterative PKS and 
eight deoxysugars, one of which is a unique nitro sugar moiety. Everninomycin 
can be produced by several different microorganisms such as Micromonospora 
carbonacea var. africana NRRL 15099 and Micromonospora carbonacea var. 
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aurantiaca NRRL 2997. The biosynthetic gene clusters of everninomycin from 
those producing strains have already been reported. In the everninomycin 
biosynthetic gene clusters, there are more than forty genes that are proposed to 
be responsible for the biosynthesis of everninomycin and at least six genes 
encoding oxidases, the functions of which have not been investigated. Therefore, 
it is hard to identify the target N-oxidase involved in the biosynthesis of nitro 
sugar from these reported everninomycin biosynthetic gene clusters only on the 
base of their sequence information.  
 Avilamycin produced by Streptomyces viridochromogenes is another 
representative example of oligosaccharide natural products and is structurally 
similar to everninomycin. Avilamycin contains a heptasaccharide chain with 
seven dexosugars and one PKS-derived dichloroisoeverninic acid moiety. The 
major difference between everninomycin and avilamycin is the absence of a nitro 
sugar in avilamycin. In 2001, the biosynthetic gene cluster for avialmycin was 
also been reported from its producer Streptomyces viridochromogenes.40 The 
availability of both the everninomycin and avilamycin biosynthetic gene clusters 
facilitates the identification of biosynthetic genes for the unique nitro sugar, 
especially for the formation of nitro group, from everninomycin gene cluster 
through comparing their identified biosynthetic gene clusters (figure 4-03).  
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Figure 4-03. Chemical structures of avilamycin from Streptomyces 
viridochromogenes Tu57  and everninomycin from Micromonospora afircana. 
 
After comparing the biosynthetic gene clusters of everninomycin and 
avilamycin, nine genes (orf37/43, orf38/44, orf39/45, orf40/46, orf41/47, orf18/3, 
orf19/4, orf35/21 and orf36/42) were identified to be present in everninomycin 
gene clusters but absent in the gene cluster of avilamycin. We speculated that 
some of these genes were responsible for the formation of the unique nitro sugar, 
L-evernitrose, in everninomycin. Sequence analysis of these genes suggested 
that four of the identified genes (orf37/43, orf38/44, orf39/45 and orf40/46) were 
probably involved in the biosynthesis of an amino sugar on the basis of their high 
similarities with the biosynthetic genes for epivancosamine in chloroeremomycin 
produced by Amycolatopsis orientalis.41 Among the remaining four genes, two of 
them were proposed to encode oxidases: orf19/4 was a copper-dependent 
oxidase and orf36/42 was a flavin-dependent oxidase. ORF19/4 was proposed to 
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be an enzyme related to primary metabolism and involved in membrane 
biosynthesis. The flavin-dependent oxidase ORF36/42 was analogous to DszC 
which has been previously demonstrated to oxidize a sulfide to a sulfone and 
IBAH which was capable of oxidizing an aliphatic amine group to an aliphatic 
hydroxyl amine group. Based upon sequence analysis of the everninomycin and 
avilamycin biosynthetic gene clusters together with the sequence similarity 
between ORF36/42 and other flavin-dependent oxidases, we proposed that 
ORF36/42 encoded a flavin-dependent N-oxidase which was responsible for the 
oxidation reaction from an amino sugar to a nitro sugar at the nucleotide stage.  
 Analogs of ORF36/42 were also identified from the identified biosynthetic 
gene clusters of two other nitro sugar containing natural products: rubradirin 
produced by Streptomyces achromogenes var. rubradiris and kijanimicin 
produced by Actinomadura kijaniata. ORF36/42 showed high similarity with 
RubN8 from the rubradirin biosynthetic gene cluster and KijD8 from the 
kijanimicin biosynthetic gene cluster. We speculated that all three of these flavin-
dependent oxidases were responsible for the formation of the corresponding nitro 
groups in these nitro sugar containing natural products.  
 An NDP activated amino sugar was proposed to be the precursor of the 
nitro sugar existing in everninomycin based upon the fact that “compound 5” 
could also be produced by the everninomycin producer M. africana and the 
existence of five genes possibly involved in the biosynthesis of an NDP-amino 
sugar. Among these five proteins in NDP-amino sugar biosynthesis, 
ORF23/ORF38 could be identified in both everninomycin and avilamycin 
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biosynthetic gene clusters, but we still speculated this protein was involved in the 
biosynthesis of the unique nitro sugar in everninomycin because this protein was 
proposed to catalyze the 2,3-dehydration of NDP-4-keto-6-deoxy-α-D-glucose, a 
key biosynthetic step for sugars in natural products. ORF37/ORF43 was 
proposed to be an aminotransferase based upon its similarity with EvaB in NDP-
L-epivancosamine biosynthesis, RubN4 in NDP-D-rubranitrose biosynthesis and 
KijD2 in NDP-D-kijanose biosynthesis. ORF38/ORF44 was proposed to be a C-
methyltransferase because of its high similarity with EvaC in NDP-L-
epivancosamine biosynthesis, RubN7 in NDP-D-rubranitrose biosynthesis and 
KijD1 in NDP-D-kijanose biosynthesis. ORF40/46 was proposed to be a 
ketoreductase on the base of its similarity with EvaE in NDP-L-epivancosamine 
biosynthesis and RubN6 in NDP-D-rubranitrose biosynthesis. ORF39/45 was 
proposed to be a C-5 epimerase because it showed high similarity with EvaD in 
NDP-L-epivancosamine biosynthesis. In the biosynthetic pathways of NDP-D-
rubranitrose and NDP-D-kijanose, the absence of a C-5 epimerase suggested 
that these two nitro sugars should be assigned the D-configuration. In NDP-D-
kijanose, the C-4 keto group should not be reduced and an amino group was 
proposed to be transferred to this C-4 position because of the existence of one 
additional aminotransferase, which was different from the biosynthetic pathways 
of the three other amino/nitro sugars (table 4-01). The biosynthetic pathway for 
TDP-L-evernitrose from everninomycin (M. africana) is elucidated in figure 4-04.  
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Table 4-01. Biosynthetic genes for the biosynthesis of NDP-
nitrosugar/aminosugar in everninomycin (M. africana), everninomycin (M. 
aurantiaca), rubradirin (S. rubradiris), kijanimicin (Actinomadura kijaniata), 
chloroeremomycin (Amycolatopsis orientalis), dibenzothiophene (Rhodococcus 
erythropolis) and valanimycin (Streptomyces viridifaciens). The protein 
sequences from everninomycin (M. africana) were used as the basis with 
identity/similarity underneath other proteins. C-4-aminotransferase KijD7 is 
unique to kijanimicin and does not have homolog in other biosynthetic gene 
clusters. 
 
Natural product 
C2,3- 
dehydrase 
C-3 -
aminotransferase 
C-3-
methyltransferase 
C4-
ketoreductase 
C-5-
epimerase 
C-4-
aminotransferase oxidase 
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(M. africana) 
ORF23 ORF37 ORF38 ORF40 ORF39  ORF36 
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(M. aurantiaca) 
ORF38 
69/78% 
ORF43 
78/85% 
ORF44 
81/85% 
ORF46 
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ORF45 
74/85% 
 ORF42 
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rubradirin 
 
RubN3 
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RubN4 
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RubN5 
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RubN6 
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  RubN8 
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KijB1 
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ORF24 
52/67% 
ORF26 
58/74% 
  
dibenzothiophene 
slufone 
      DszC 
23/35% 
valanimycin       IBAH 
23/38% 
 
 
 
 
 
 
Figure 4-04. Biosynthetic pathway for TDP-L-evernitrose from everninomycin 
(Micromonospora. africana). 
 
In 1992, a very interesting phenomenon was reported related to the 
biosynthesis of rubradirin: when the rubradirin producer Streptomyces rubradiris 
was cultured in the complete darkness, another structurally related natural 
product, protorubradirin with a nitroso group, instead of rubradirin, was detected 
from the fermentation broth and the purified. Protorubradirin could be converted 
to rubradirin after it was exposed to light.42 Therefore, protorubradirin was most 
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likely the direct product of Streptomyces rubradiris. The oxidation of a nitroso 
sugar to a nitro sugar was proposed to be catalyzed by an in vitro chemical 
reaction. On the basis of the report about the identification of protorubradirin and 
the conversation of protorubradirin to rubradirin, we speculated that an NDP-
amino sugar should be first oxidized to an NDP-nitroso sugar and then attached 
to its aglycon acceptor by a glycosyltransferase. The oxidation of the nitroso 
sugar was proposed to occur after the excretion of nitroso sugar containing 
natural product.  
Expression of nitrososynthase from E. coli BL21(DE3) and preparation of TDP-
amino sugar 
 Several different Micromonospora strains have the ability to produce 
everninomycins. We chose one everninomycin producer, Micromonospora 
carbonacea var. africana, as the model stain to investigate the biosynthesis of 
nitro sugar moiety. The biosynthetic gene cluster of everninomycin was identified 
from the genome in M. africana and one gene, orf36, was proposed to encode a 
flavin-dependent nitrososynthase for the oxidation of an NDP-amino sugar to an 
NDP-nitro sugar.  
 M. africana (NRRL 15099) was provided by Agricultural Research Service 
Culture Collection. Genomic DNA of M. africana was extracted and used as 
template for the PCR amplification of orf36. Orf36 was cloned into NdeI/HindIII 
sites of plasmid pET28a to yield recombination plasmid pET-28N for the 
expression of an N-terminal hexahistidine fusion protein with ORF36. ORF36 
with an N-terminal his tag was successfully expressed in E. coli BL21(DE3), after 
the induction by isopropyl ߚ –D-1-thiogalactopyranoside (IPTG), as a soluble 
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protein. Subsequently, ORF36 was purified to homogeneity and desalted using 
Fast protein liquid chromatography (FPLC) (figure 4-05). ORF36 which has been 
cloned from the genomic DNA of M. africana (NRRL 15099) and purified from E. 
coli BL21(DE3) was used for further enzymatic characterization of its 
nitrososynthase activity.  
 
 
 
 
 
 
 
 
 
 
Figure 4-05. Expression of ORF36 in E. coli BL21(DE3) (From left to right, Lane 
1: Molecular weight markers; Lane 2: Uninduced total protein extract; Lane 3 
Induced total protein; Lane 4: Flow-through of Ni2+ column; Lane 5: Pooled 
fractions from Ni2+ column; Lane 6: Desalted fraction). 
 
 Everninomycin contains an L-epivancosamine with a nitro group at the C3 
position. As has been previously described, an NDP-amino sugar was proposed 
to be the direct precursor of the nitrososynthase ORF36. However, this required 
NDP-amino sugar for everninomycin biosynthesis was not commercially available, 
so this proposed substrate has to be synthesized to complete the enzymatic 
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characterization of ORF36 from everninomycin producer M. africana. 
 To date there are mainly three approaches for the preparation of NDP 
activated deoxysugars: (1) total chemical synthesis through multiple steps to 
obtain NDP-dexosygars, (2) utilizing the reversible reaction mediated by 
glycosyltranferase to obtain NDP-dexosygars from sugar containing natural 
products in the presence of excess NDP (figure 4-06), (3) preparation of NDP-
amino sugars from their commercially available substrate through multiple 
enzymatic reactions (figure 4-07). The problem with applying these approaches 
to prepare the NDP-amino sugar for the characterization of ORF36 was that it is 
not trivial to synthesize this structurally unique NDP-amino sugar through either 
chemical or enzymatic syntheses, although these methods were demonstrated to 
be feasible for the production of NDP-deoxysugars.  
 
 
 
 
 
 
 
 
Figure 4-06.  Preparation of NDP-deoxysugars by the reversible reactions 
catalyzed by glycosyltransferases (VinC from S. halstedii as an example). 
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Figure 4-07. Preparation of NDP-deoxysugars using enzymatic reactions (NDP-
L-epivancosamine as an example). 
 
 Professor Daniel Kahne from Harvard University kindly provided us with a 
structurally similar TDP-deoxysugar, TDP α,β-epi-L-vancosamine azide, from 
which we were able to prepare the NDP-amino sugar required in the enzymatic 
reaction for nitrososynthase ORF36. The NDP-amino sugar for ORF36, L-TDP-
epi-vancosamine, was chemically prepared by the reduction of TDP α,β-epi-L-
vancosamine azide using tris(2-carboxyethyl)phosphine (TCEP).  HPLC-MS 
analysis showed that 95% of TDP α,β-epi-L-vancosamine azide could be 
reduced to L-TDP-epi-vancosamine for further characterization of ORF36 
enzymatic activity. L-TDP-epi-vancosamine that we chemically prepared differs 
from the L-epivancosamine involved in everninomycin biosynthesis in containing 
an hydroxyl group instead of an OCH3 group at C4 position (figure 4-08). 
However, everninomycin producer M. africana can also produce a structurally 
similar natural product, Sch 58773, which contains a nitro sugar with a hydroxyl 
group at C-4 position43, indicating that the biosynthesis of nitro group is not affect 
by the presence of hydroxyl group or OCH3 group at C-4 position (figure 4-09).  
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Figure 04-08. Reduction of TDP-epi-L-vancosamine-N3 by TCEP to yield TDP-
epi-L-vancosamine-NH2. 
 
 
 
 
 
 
 
 
Figure 04-09. Everninomycin and Sch 58773 produced by Micromonospora 
africana.  
 
 
Functional characterization of nitrososynthase ORF36 
 ORF36 from the everninomycin biosynthetic gene cluster in M. africana 
was proposed to be a flavin-dependent N-oxidase for the oxidation of an amino 
sugar to a nitroso sugar because of its high sequence similarity with other flavin-
dependent oxidases such as DszC which could oxidize a sulfide to a sulfone and 
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IBAH which was responsible for the oxidation of an aliphatic amine to a aliphatic 
hydroxylamine. We speculated that ORF36 was also an N-oxidase which could 
oxidize an amino sugar to a nitrososugar and required the existence of reduced 
flavin for its activity.  
 To reconstitute the enzymatic activity of ORF36 in vitro, a flavin reductase 
was necessary to provide reduced flavin for ORF36 in the presence of excess 
NADPH. The in vitro reconstitution of nitrososynthase ORF36 required flavin, 
NADPH and flavin reductase. A commercially available flavin reductase from 
Photobacterium fischeri was directly utilized for flavin-dependent oxidase ORF36. 
The analysis of the enzymatic reaction catalyzed by ORF36 was carried out 
using HPLC-MS. HPLC-MS results showed that ORF36 was a nitrososynthase 
which was able to oxidize L-TDP-epi-vancosamine (m/z=544) to its 
corresponding nitroso product (m/z=560) through a hydroxylamine intermediate 
(m/z=558) (figure 4-10, 4-11).  
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Figure 4-10. Oxidation reaction catalyzed by nitrososynthase ORF36 from 
everninomycin biosynthetic gene cluster in M. africana.  
 
 The oxidation reaction from a TDP-aminosugar to a TDP-nitrososugar has 
been demonstrated to be mediated by ORF36. This oxidation reaction is a flavin-
dependent reaction in which a flavin reductase is required to provide reduced 
flavin for N-oxidase ORF36 in the presence of excess NADPH. A TDP-
hydroxylaminosugar is proposed to be an intermediate in the ORF36 catalyzed 
oxidation reaction. The proposed mechanism for flavin-dependent N-oxidase is 
elucidated in figure 4-12.   
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Figure 4-11. MS and Tandem MS of product ions for ORF36 catalyzed reactions. 
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Figure 4-12. Proposed pathway for nitrososynthase ORF36 oxygenation reaction.  
 
 The function of ORF36 from the everninomycin biosynthetic gene cluster 
in M. africana has been demonstrated to be a nitrososynthase. In the case of 
rubradirin, which is another nitrosugar containing natural product produced by S. 
rubradirius, it has been proven that actually protorubradirin containing a 
nitrososugar is the direct product and oxidized to rubradirin by oxygen and UV 
light outside the cells via a chemical reaction. In our laboratory, another graduate 
student Ahmad Al-Mestarihi studied the function of RubN8, which is an ORF36 
analog from rubradirin biosynthetic gene cluster. RubN8 was also confirmed to 
be an N-oxidase responsible for the oxidation of a TDP-aminosugar to a TDP-
nitrososugar in rubradirin biosynthesis. In the process of studying the 
biochemical function of RubN8, Ahmad Al-Mestarihi also tried to identify whether 
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the TDP-nitrososugar could be converted to a TDP-nitrosugar by a chemical 
reaction. The RubN8 oxidation reaction system which contained the final product, 
a TDP-nitrososugar, was exposed to strong UV light (350 nm) and oxygen for two 
hours, but the compounds in this reaction system decomposed and no expected 
TDP-nitrosugar could be detected, possibly because those TDP-sugars were 
unstable or the reaction conditions were not suitable for the chemical oxidation 
from a TDP-nitrososugar to a TDP-nitrosugar. The biosynthetic mechanism for 
the oxidation from nitrososugar to nitrosugar needs further investigation.  
 
Materials and Methods 
Bacterial strains, Plasmids and Materials 
All reagents were obtained from Sigma-Aldrich corporation and used 
without further purification unless otherwise noted. E. Coli TOP10 and BL21(DE3) 
competent cells were obtained from Invitrogen Inc. (Carlsbad, CA) and Novagen 
(Madison, WI), respectively. Restriction endonucleases and T4 DNA ligase were 
obtained from New England Biolabs (Ipswich, MA). The pET28a expression 
vector was purchased from Novagen Inc. Taqplus DNA polymerase was 
purchased from Stratagene Inc. (La Jolla, CA). DNA primers were obtained from 
Operon Biotechnologies (Huntsville, AL). Solvents were reagent grade and were 
further dried when necessary. Analytical thin-layer chromatography was 
performed on glass plates precoated with silica gel (250 μm, Sorbent 
Technologies), with detection by UV and/or spraying with H2SO4 (50%). Flash 
chromatography was carried out on silica gel (60 Å, 32-63 μm), purchased from 
 
 
160 
Sorbent Technologies. Analytical HPLC of synthetic reaction mixtures was 
performed on a Hewlett-Packard 1100 series instrument using a Phenomenex 
Luna 5 μm C18 column (250 mm x 4.6 mm). Compounds bearing a thymidine 
chromophore were monitored at an absorbance of 270 nm. Synthetic reactions 
were monitored by HPLC using gradient A (a linear gradient from H2O/0.1% 
NH4HCO3 to 100% MeOH/0.1% NH4HCO3 over the course of 25 min). 
Preparative HPLC was performed on a Varian ProStar instrument using a 
Phenomenex Luna 10 μm C18 column (250 mm x 50 mm). NMR spectra were 
recorded on Varian Innova 400 or 500 MHz spectrometers. Mass spectra (ESI) 
for synthetic compounds were obtained using an Agilent Technologies LC/MSD 
instrument (Model #G1956B). 
Preparation of Thymidine 5'-(3-amino-2,3,6-trideoxy-3-C-methyl-α,β-l-arabino-
hexopyranosyl diphosphate), TDP α,β-epi-L-vancosamine azide.  
The protected TDP epi-vancosamine (reference: Oberthur, M.; Leimkuhler, 
C.; Kahne, D., Org Lett 2004, 6, (17), 2873-76) (38 mg, 60 μmol) was dissolved 
in MeOH/H2O/Et3N (2:2:1, 4 mL) and stirred at room temperature for 16 h. 
Following evaporation, the residue was redissolved in MeOH/H2O (2:1, 2 mL) 
and purified by reversed-phase HPLC. 2.25 (18 mg, 92%) was obtained as its 
ammonium salt, tR = 9.0 min, method A. 1H NMR (400 MHz, D2O): 2.25β: δ = 
7.62 (s, 1 H, 6-H), 6.24 – 6.21 (m, 1 H, 1'-H), 5.22 – 5.17 (dt, J1,2b = J1,P = 9.0, 
J1,2a = 2.1 Hz, 1 H, 1"-H), 4.47 (m, 1 H, 3'-H), 4.02 (m, 3 H, 4'-H, 5'-H2), 3.52–
3.47 (m, 1 H, 5"-H), 3.16 (d, J4,5 = 10 Hz, 1 H, 4"-H), 2.22 - 2.08 (m, 2 H, 2'-H2) 
2.07 (d, ,J2a,2b = 12.6 Hz, 1 H, 2"-Ha ), 1.71 (s, 3 H, thymidine CH3), 1.56-1.51 (dd, 
J1,2b = 9.0, J2a,2b = 12.6 Hz, 1 H, 2"-Hb), 1.25 (s, 3 H, 3"-CH3), 1.13 (d, J5,6 = 6.4 
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Hz, 3 H, 6"-H3); 31P NMR (162 MHz, CD3OD): δ = –10.61, –12.82. LRMS (ESI) 
for C17H27N5O13P2 (570.12): 571 [M–1H]–. 
Cloning and overexpression of ORF36 
The gene encoding ORF36 was amplified from genomic DNA of 
Micromonospora carbonacea var. africana (NRRL 15099) using the following 
primers: 5'GCACATATGGCGGCGGATCTTCGCGC3' and 
5'TTGAAGCTTTTATTACGCCGAGGTCCGGGAGC 3' (NdeI and HindIII 
restriction enzyme sites underlined). PCR reactions were carried out using 
Taqplus DNA polymerase according to the manufacture’s protocol. Subcloning of 
orf36 into the NdeI/HindIII sites of pET28a yielded recombinant plasmid pET28-
36N for expression as an N-terminal hexahistidine fusion protein with ORF36. 
Plasmid pET28-36N was transformed into E. Coli BL21(DE3) for heterologous 
expression of ORF36. Cultures of E. Coli BL21(DE3)/pET28-36N were grown at 
37°C to an OD600 of 0.6, at which point the culture was induced with 0.1 mM 
isopropyl-beta-Dthiogalactopyranoside (IPTG) and grown an additional 6 hours at 
28°C. Cells were harvested by centrifugation and stored at -80°C until needed. 
IPTG induced E. Coli BL21(DE3)/pET28-36N cells were resuspended in buffer A 
(20mM Imidazole, 0.5 M NaCl, 20mM Tris-HCl, pH 7.5) and lysed by sonication. 
The lysate was loaded onto a charged 5-ml Histrap crude column (Amersham 
Biosciences) and purified by FPLC at a flow rate of 5 ml/min. The column was 
washed with buffer A (20mM Imidazole, 0.5 M NaCl, 20 mM Tris-Cl, pH 7.5) and 
buffer B (500mM Imidazole, 0.5 M NaCl, 20 mM Tris-Cl, pH 7.5) using a step 
gradient. Fractions containing ORF36 were analyzed by SDS-page and buffer 
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was exchanged via a desalting column (HisTrap) using buffer C (20mM Tris-Cl, 
1mM dithiothreitol and 5% glycerol, pH 7.5) and stored at -80 °C until assayed. 
Preparation of L-TDP-epi-vancosamine  
L-TDP-epi-vancosamine (4-O-desmethyl L-TDPevernosamine) was 
prepared by reduction of a synthetic azide congener 5 (0.5 mM) with 1 mM tris(2-
carboxyethyl)phosphine (TCEP) in 20 mM Tris-HCl (pH 7.5) at 22°C for 24 hours. 
Amino sugar was stored in small aliquots at -80 °C until immediately prior to 
assays. HPLC/MS, performed for the reduction of the azide congener as 
described below for L-TDP-epi-vancosamine enzymatic reaction, indicated the 
extent of reaction was > 96%. 
ORF36 enzymatic reactions  
Solutions of flavin adenine dinucleotide (FAD) and nicotinamide adenine 
dinucleotide phosphate (NADPH) were made in 20 mM Tris-HCl pH 7.5 
immediately before use. The concentration of substrate L-TDP-epi-vancosamine 
was determined by comparison of absorbance values of stock solutions to a TDP 
standard curve at 270 nm using a Nanodrop 1000 UV spectrometer (Thermo 
Fisher Inc). ORF36 were aliquoted in storage buffer [20 mM Tris.HCl, 5% 
glycerol, 1 mM DTT, pH 7.5], stored at -80 °C and thawed directly before use. 
Flavin reductase from Photobacterium fischeri (Roche Diagnostics GmbH, 
Mannheim, Germany) was stored in 40% glycerol, 1 mM EDTA, 0.1 mM DTT and 
50 mM potassium phosphate, pH 7.0. The catalase and superoxide dismutase 
enzymes (Sigma Chemicals) were made in [20 mM Tris.HCl 40% glycerol, pH 
7.5]. In a total volume of 50 μL, 250 μM of the substrate, L-TDP-epi-vancosamine, 
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was incubated with 30 μM FAD, 1 U/mL catalase, 1 U/mL superoxide dismutase, 
0.001 mg/mL flavin reductase, and 0.4 – 2.0 mM NADPH. The reaction was 
initiated by the addition of ORF36. The time course of the reaction was followed 
by HPLC/MS at 30°C. 
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